**CURRICULUM VITAE**

**Maria Fernanda Leal Lopes-Virella. M.D., Ph**.**D.**

**Office Address:** Ralph H. Johnson VA Medical Center

Medical University of SC

Strom Thurmond Building, Rm 529

114 Doughty Street

Charleston, SC 29425

\(843\) 789- 6823

FAX (843) 789- 6854

Email \<virellam@musc.edu\>

**DEGREES OBTAINED**

> 7/31/1967 School of Medicine M.D. with Honors

University of Lisbon

Lisbon, Portugal

5/12/1990 School of Medicine Ph.D. with Honors

University of Lisbon Internal Medicine and

Lisbon, Portugal Biochemistry

# POST-GRADUATE CLINICAL training 

1967-68 Internship

Hospital Sta Maria, Lisbon, Portugal

1970-1973 Resident in Medicine

Hospital Sta Maria, Lisbon, Portugal

1973-1975 Resident in Clinical Pathology

Hospital Sta Maria, Lisbon, Portugal

1975-1977 Fellow in Endocrinology

Medical University of SC, Charleston, SC

1977-1979 Resident in Clinical Pathology, MUSC, Charleston, SC

1979 Fellow in Clinical Pathology

Medical University of SC, Charleston, SC

######## 

######## POST-GRADUATE RESEARCH training 

1968-1969 University of Birmingham Medical School, UK, Post-doctoral
Fellow

1971-1973 University of Lisbon, School of Medicine, Portugal

Research scholarship: National Institutes of High Education

> 1975-1977 Medical University of SC, U.S.A, Fellow in Endocrinology.
>
> 1977 Massachusetts Institute of Technology, Cambridge, USA
>
> Robert S. Lees, Mentor

##### CERTIFICATION AND LICENSURE 

1968 License to practice Medicine, Portugal

1975 Educational Council for Foreign Medical Students

> 1979 South Carolina State Board of Medical Examiners (FLEX)
>
> 1979 State of South Carolina License

1984 Board Certification by the American Board of Pathology

2005 Board Certification by the American Board of Lipidology

#### 

#### ACADEMIC APPOINTMENTS 

1977-1979 Instructor in Medicine, Medical University of South Carolina,
Charleston, SC

> 1979-1984 Assistant Professor, Division of Endocrinology, Metabolism
> and Nutrition, Department of Medicine, Medical University of South
> Carolina, Charleston, SC
>
> 1981-1984 Assistant Professor, Department of Pathology, Medical
> University of South Carolina, Charleston, SC (joint appointment)
>
> 1984-1989 Associate Professor, Division of Endocrinology, Metabolism
> and Nutrition, Department of Medicine and Department of Pathology,
> MUSC, Charleston, SC
>
> 1987-present Tenure, Medical University of South Carolina, Charleston,
> SC
>
> 1989-Present1978 Professor, Division of Endocrinology, Diabetes and
> Medical Genetics, Department of Medicine and Department of Pathology,
> Medical University of South Carolina, Charleston, SC (primary
> appointment)
>
> 1991-Present Professor, Department of Microbiology and Immunology,
> MUSC, Charleston, SC (joint appointment)

2003. Professor, Oral and Community Health Sciences Division, Department
      > of Stomatology, College of Dental Medicine, MUSC, Charleston, SC
      > (joint appointment)

```{=html}
<!-- -->
```
2003. Professor, Bioengineering Department, Medical University of South
      > Carolina and Clemson University (joint appointment)

> **HOSPITAL APPOINTMENTS**
>
> 1980-present Attending, Medical University of South Carolina,
> Charleston, SC
>
> 1981-87 Co-Director, Diabetic and Lipid Clinic, MUSC, Charleston, SC
>
> 1984-present Staff Physician, Ralph H. Johnson VA Medical Center,
> Charleston, SC
>
> 1987-Present Chief, Nutrition Support Team, Ralph H. Johnson VA
> Medical Center, Charleston, SC
>
> 1987-Present Chief, Clinical Chemistry, Immunology and Serology and
> Microbiology Sections, Laboratory Services, Ralph H. Johnson VA
> Medical Center, Charleston, SC
>
> 1989-1997 Co-Director of the Lipid Clinic, Ralph H. Johnson VA Medical
> Center, Charleston, SC
>
> 1996-Present Co-Director, Cholesterol Clinic, Medical University of
> SC, Charleston, SC

##### HONORS AND AWARDS

1978-83 Special Emphasis Research Career Award, National Heart, Lung and
Blood Institute and National Institutes of Arthritis, Metabolism and
Digestive Diseases

1984-86 Clinical Investigator, VA Research and Development Award

1986 John A. Colwell Award for Outstanding Contributions to Diabetes
Research, American Diabetes Association, South Carolina Affiliate

1987 Developing Scholar Award - Health Sciences Foundation of the
Medical University of South Carolina

1987 Squib-Preis Award for the best publication submitted to \"Die
Osterreichisch Gesellschaft für Innere Medizin\"

1996-1998 Chair, Council on Complications, American Diabetes Association

1999-2000 President-Elect, Southeast Lipid Association

2000-2001 President, Southeast Lipid Association

2001 Edwin Bierman Lectureship Award, American Diabetes Association

2002-present Alpha Omega Alpha

2003, 2006 Mary Jane Kugel Award, JDRFI, May 2003 and 2006

2008. Member, Board of Directors, National Lipid Association

```{=html}
<!-- -->
```
2011. Member of the American Board of Clinical Lipidology

```{=html}
<!-- -->
```
2005. VA Vision 7 Henry Middleton Award for Excellence in Research

2008 Member, Institute of Medicine, National Academies

# MAJOR RESEARCH INTERESTS

> Glycation/oxidation of lipoproteins and lipoprotein metabolism in
> diabetes
>
> Macrophage activation and immune-mediated mechanisms of complications
> in diabetes

LDL receptor gene regulation

Mechanisms of endothelial dysfunction and plaque rupture

##### 

##### PROFESSIONAL ORGANIZATIONS

Fellow of the American Heart Association

Fellow, Council on Arteriosclerosis, Thrombosis and Vascular Biology,
AHA

Fellow, Council on Nutrition, Physical Activity and Metabolism, AHA

Fellow, American College of Nutrition

Fellow, American College of Pathology

American Diabetes Association

American Federation for Clinical Research

Southern Society for Clinical Investigation

American Society for Nutritional Sciences

Society for International Nutrition Research

Southeast Lipid Association, Past President

National Lipid Association, Board of Directors

**MAJOR COMMITTEE ASSIGNEMENTS**

# National and Regional 

1983-1986 Representative of the Medical University of South Carolina to
the American Federation for Clinical Research and Member of the
Legislation Liaison Group for the American Federation for Clinical
Research.

1984-1990 Member of the Lipid-Apolipoprotein Standardization
Subcommittee of the International Union of Immunological Societies.

1988 Representative of the Medical University of South Carolina to the
Southeastern Region of Medical Educators in Nutrition.

1993-1996 Member of the Abstract Review Committee for the American
Diabetes Association Annual meetings on the category of
Lipids/Lipoproteins.

1995-1999 Member, National Lipid Education Council.

1997-2001 Member of the Abstract Review Committee for the American
Diabetes Association Annual meetings on the category of Complications.

2002. Member, Research Career Scientist Evaluation Committee, Department
      of Veterans Affairs.

2003-Present Member, Research Career Development Committee, Department
of Veterans Affairs.

2005-2011- Member, American Board of Clinical Lipidology

# Medical University of South Carolina 

1983 Chair, Task Force to create a course of Clinical Nutrition for
Medical Students

1983\. Member, Task Force to create a course of Exercise Physiology

1985-1988 Member, University Research Committee.

1986-1990 Chair, Department of Medicine Research Development Committee,

1986-1989 Member, Molecular Cell Biology Program Admissions and
Recruitment Committee.

1987 Member, Nutrition Task Force (Wellness Center).

1989-1991, 1997-00 Member, Faculty Senate, Medical University of SC

1989-2002 Member, Medical School Curriculum Committee

1998-2001 Member, Advisory Committee, MUSC Dietetic Internship Program.

1998-2001 Member, College of Medicine Appointments, Promotion and Tenure

Committee, Medical University of SC

2003- Member, College of Medicine Tenure Committee, MUSC

2004- Member, Steering Committee for the NIDDK Short-Term Research
Training Program for Health professional Students

2004- Member, Steering Committee Lipidomics and Pathobiology Training
Program

**Ralph H. Johnson VA Medical Center**

1984-1986 Member, VA Research and Development Committee.

1988-1991 Chair, Space Subcommittee, VA Research Development Committee.

1990-1994 Chair, VA Drug Utilization Evaluation Committee.

1991-Present Chair, VA Nutrition Committee.

2000. Chair, VA Research and Development Committee

2004- Member, VA Space Committee

2004-2008 Chair, VA Research and Development Committee

**Editorial Boards and EDITORIAL ADVISORY PANELS**

1990-Present Portuguese Journal of Nutrition, Editorial Board

1992-1995 Diabetes Care, Editorial Board

1992-1995 Journal of Women\'s Health, Advisory Committee

1992. Diabetes, Guest Editor

2002-present Editor, National Lipid Association Newsletter

2007-present Associate Editor, Journal of Clinical Lipidology

*Ad Hoc Reviewer for:*

American Journal of Clinical Nutrition; American Journal of Physiology;
Arteriosclerosis, Thrombosis and Vascular Biology; Atherosclerosis;
Biochimica Biophysica Acta; Circulation, Clinical Chemistry; Clinical
Immunology and Immunopathology; Diabetes; Diabetes Care ; Diabetic
Medicine; Diabetologia; European Journal of Clinical Investigation;
Journal of the American Medical Association; Journal of Clinical
Investigation; Journal of Lipid Research, Journal of Pharmacology and
Experimental Therapeutics; Metabolism; New England Journal of Medicine;
Proceedings of the National Academy of Sciences.

# 

# GRANT REVIEW STUDY SECTIONS

1988-1991 American Diabetes Association, National Research Review
Committee.

1989 NIH Program Project Site Visit (PI: A.Gotto, Baylor College of
Medicine,

Houston, Texas.

1991-1995 Nutrition Study Section, National Institutes of Health.

1991-1994 Endocrinology Merit Review Board, Department of Veterans
Affairs

1995-2004 VA Career Development Programs (Endocrinology, Cardiovascular
and Geriatrics)-Ad Hoc Reviewer

1995-Present VA Merit Review Boards (Endocrinology, Cardiovascular and
Immunology)-Ad Hoc Reviewer

1995-1999 National Institutes of Health Reviewers Reserve.

1996 NIH Program Project Site Visit (PI: A.Chait, Univ of Seattle,
Seattle, WA).

1998 American Heart Association Mid-Atlantic Peer Review Research
Consortium.

1998-2001 Member, Research Career Scientist Evaluation Committee,
Department of Veterans Affairs

2001-present Member, Medical Science Review Committee, Juvenile Diabetes
Research

Foundation International

2004-2006 Member, Research Career Development Committee, Department of
Veterans Affairs

2005 Member, Integrative Physiology of Obesity and Diabetes (IPOD) Study
Section, National Institutes of Health (Ad Hoc reviewer)

2005 NIH Program Project Special Review Committee (PI: Alan Tall,
Columbia University, NewYork NY)

2008-2011 Member, SubCommittee for Endocrinology A , Department of
Veterans Affairs Joint Biomedical Laboratory Research and development
and Clinical Science Research and development Scientific Merit Review
Board

2008-2011 Member, Vascular Biology Study Section, NIH

# EXTRAMURAL RESEARCH FUNDING (PAST) 

# Research Grants

1\. NHLBI and NIADDK, NIH, AM00591 SRC. "SERCA: Diabetes Mellitus --
Cardiovascular \" PI, \$235,405 (direct costs), 7/1/78-6/30/83.

2\. American Diabetes Association: "Study of Proteinuria as an Index of
Renal Function in Diabetes,\" PI, \$5,000 (direct costs),
11/1/79-6/30/81.

3\. American Heart Association, SC Chapter: \"Cell Lipoprotein
Interactions in Insulin Dependent Diabetes Mellitus," PI, \$12,000
(direct costs), 7/1/83-6/30/84.

4\. NHLBI, NIH, HL30929. \"Lipoprotein Metabolism and Cell Lipoprotein
Interactions,\" PI, \$202,597 (direct costs), 8/1/83-7/30/87.

5\. VA Career Development Program: \"VA Clinical Investigator Award,\"
PI, \$265,000, 1/1/84-12/31/86.

6\. VA Merit Review Research Program: \"Lipoprotein Metabolism and
Cell-Lipoprotein Interactions in Diabetes Mellitus" --Principal
investigator

\$120,438, 4/1/85-3/31/88 (years 1-3); \$320,500, 4/1/88-3/31/93 (years
4-8); \$564,645, 4/1/93-3/31/98 (years 9-13

7\. Diabetes Treatment Centers of America : \"The Pathogenesis of
Arteriosclerosis in Diabetes Mellitus. The Role of Abnormal
Platelet-Lipoprotein Interactions," PI, \$30,000 (direct costs),
1/1/87-12/31/88.

8\. American Heart Association : \"Cyclosporine, Lipoprotein Metabolism
and Arteriosclerosis in Heart Transplant Patients," PI, \$35,957,
7/1/90-6/30/92.

9\. NIH-1 R01 NS29627-01: "Southeastern Consortium on Racial Differences
in Strokes," \$160,438 (sub-contract). PI- Kenneth J. Gaines, University
of Tennessee, Memphis, TN (total budget: \$1,753,458), 7/1/91-6/30/95.

10\. NHLBI, NIH, R01-HL46815 : \"Macrophage Activation and Lipoprotein
Metabolism,\" PI, \$634,155, 8/1/94-11/30/2002

11\. American Heart Association: "Molecular Mechanisms of LDL-receptor
upregulation in Cholesterol-laden Cells," PI, \$165,000, 1/1/98-1/1/99.

12\. MUSC Heart Research Center: "Post-transcriptional Regulation of
Scavenger Receptor Expression," PI, \$150,000, 12/1/97-11/30/01.

13\. NIH-R01 DK34818: "Epidemiology of Diabetic complications: Phase
II," PI: Trevor Orchard, sub-contract to Lopes-Virella, \$90,873,
3/1/1999-2/28/01.

14\. Merck & Co: "Low Density Lipoprotein Oxidation and Endothelial
Dysfunction in NIDDM.

Effect of Simvastatin Therapy," PI, \$32,841, 6/1/99-5/31/01.

15.NIH, PO1 HL-55782 and JDFI: \"Markers and Mechanisms of Macrovascular
Disease in IDDM" (Garvey W.T. -P.I.), Project 2: "Modified LDL
Autoimmunity and Vascular Diseases in IDDM," Lopes-Virella - Project
Leader, \$580,639, 7/1/96 - 8/31/01 (years 1-5).

16.VA Merit Review Research Program: \"Lipoprotein Metabolism and
Cell-Lipoprotein Interactions in Diabetes Mellitus" --Principal
investigator, \$120,438, 4/1/85-3/31/88 (years 1-3); \$320,500,
4/1/88-3/31/93 (years 4-8); \$564,645, 4/1/93-3/31/98 (years 9-13);
\$519,800, 4/1/98-3/31/03 (years 14-18)

17\. Merck. Lipid Preceptorship Program, PI: Lopes-Virella, \$60,000,
4/15/99-12/31/03

18\. Juvenile Diabetes Foundation International: "Immune Mechanisms of
Micro/Macrovascular Disease in Type 1 Diabetes", Principal Investigator,
\$675,000 (direct costs), 8/1/02-7/31/05

**Clinical Trials (completed)**

1\. Clinical Research International : \"Lovastatin Dose Ranging
Multicenter Study in Patients with Type II Hypercholesterolemia,\" PI,
\$50,000, 7/1/87-6/30/90.

2\. Merck Sharp & Dohme: \"Simvastatin Compared to Lovastatin in
Patients with Hypercholesterolemia,\" PI, \$20,232, 7/1/89-6/30/91.

3\. In Vivo, Inc.: "Effect of Pravastatin on Controlling
Hypercholesterolemia: A Special Patient Population," PI, \$7,768,
12/1/91-8/31/92.

4\. Sandoz : "An Open-Label Study of Fluvastatin in the Treatment of
Patients with Hypercholesterolemia in Clinical Practice Settings," PI,
\$7,200, 6/1/93-6/1/94.

5\. Merck & Co: "ExPRESS-FH (A Multicenter, Open Label Expanded Use
Study to Evaluate Tolerability of Simvastatin 80 mg in Patients with
Heterozygous Familial Hypercholesterolemia," PI, \$32,000,
6/1/97-12/31/98

6\. Bristol-Myers Squibb: "The Collaborative Study Group Trial: The
Effect of Irbesartan on Morbidity and Mortality in Hypertensive Patients
with Type II Diabetes and Diabetic Nephropathy," PI, \$72,200,
9/1/98-8/30/00.

7.  Parke Davis: "The Challenge Study," PI, \$69,150, 10/1/98-12/31/99.

8.  Keryx Biopharm/Medpace, Inc: The Collaborative Study Group Trial:
    The Effect of Sulodexide in Type 2 Diabetics with Microalbuminuria
    or Overt Diabetic Nephropathy; Lopes-Virella (PI), 03/01/05-07/31/08

**ONGOING** **EXTRAMURAL RESEARCH SUPPORT**

**As Principal Investigator**

1\. NIH, PO1-HL-55782: \"Markers and Mechanisms of Macrovascular Disease
in Diabetes Mellitus" \$1,894024/year 10, \$8,371,184- total for years
6-10 (9/1/2001-8/31/2007). Principal Investigator

2.  VA Merit Review Research Program: \"Lipoprotein Metabolism and
    Cell-Lipoprotein Interactions in Diabetes Mellitus" \$145,500/year,
    579,900 from 10/1/2007 to 6/30/2011 (years 23-26). Principal
    Investigator

3.  Glaxo-SmithKline/University of Oklahoma (PI:T.Lyons): Markers and
    Mechanisms of Vascular Disease in Diabetes 11/10/03-11/9/08. Current
    year direct costs: \$103,000. Entire contract direct costs:
    \$546,250. Principal Investigator for MUSC subcontract

4.  Juvenile Diabetes Foundation (1-2006-49): Immune mechanisms of
    nephropathy in type 1 diabetes. 3/1/06-2/28/09. Direct costs
    \$150,000/year, Total direct costs \$450,000.

5.  VA Research Program: VA Cooperative Study CSP #565- Nephron D study
    \$80.000/yr, Total direct costs 425,400 from 7/1/2008-6/30/2013-
    Principal Site Investigator

6.  NIH, RO1 DK081352: Biomarkers of Vascular Disease Progression in
    Type 1 Diabetes. \$443,996 /year \$1, 811,561 total from 9/1/2008 to
    7/31/2012. Principal Investigator

7.  Glaxo-SmithKline: "A clinical outcomes study of darapladib vs
    placebo in subjects with chronic coronary heart disease to compare
    the incidence of major adverse cardiovascular events (MACE).
    \$354,765.00; 10/10/2008 -- 10/12/2012. Principal Investigator

**As Co-investigator**

8.  5 P20 RR017696-04/ NIH/NCRR (PI: Steve London): South Carolina COBRE
    for Oral Health

\$1,678,135/year. 09/30/02-06/30/07. (Lopes-Virella Co-Investigator)

9.  VA Research Service: REAP (PIs J Raymond and G Gilkeson):
    Inflammatory Mediators of Renal Diseases--\$187,500/year.
    1/1/05-12/31/09. (Lopes-Virella -Co-Investigator)

10. RO1 HL 077192 NIH/NHLBI (PI: A. Jaffa) Lipoproteins, CTGF and
    Diabetic Vascular and Renal Disease. \$250,000/year.
    01/01/06-12/31/2010

11. RO1 HL (PI: S.Hammad) NIH/ NHLBI R01 HL079274-01 (PI: S. Hammad).
    Sphingolipid signaling induced by LDL-immune complexes.
    \$200,000/year, 4/1/06-3/31/2011

# EDUCATION

# Mentorship of Junior Faculty

1.  Yan Huang, MD, PhD- VA Merit Review type 2 Research Program
    "Regulation of Matrix Mettaloproteinase-1 by Oxidized LDL",
    \$286,800, 10/1/99-9/30/02.

2.  Samar Haddad, PhD , "Sphingolipid signaling induced by LDL-immune
    complexes" co-mentorship with Lina Obeid, MD- 2003-present

3.  J Fernandes, MD - COBRE for Oral Health, Leader of Project 1
    "Epidemiological Study of Periodontal Disease and Diabetes: Cytokine
    genes and Inflammation Factors "(PI of COBRE: Steve London),
    co-mentorship with JJ. Saunders, 2003-present

# Graduate Students

+-----------------+-----------------------------+---+---------------------+
| **Name**        | # Role                      | # |                     |
|                 |                             |   |                     |
|                 |                             | P |                     |
|                 |                             | r |                     |
|                 |                             | e |                     |
|                 |                             | s |                     |
|                 |                             | e |                     |
|                 |                             | n |                     |
|                 |                             | t |                     |
|                 |                             |   |                     |
|                 |                             | P |                     |
|                 |                             | o |                     |
|                 |                             | s |                     |
|                 |                             | i |                     |
|                 |                             | t |                     |
|                 |                             | i |                     |
|                 |                             | o |                     |
|                 |                             | n |                     |
+-----------------+-----------------------------+---+---------------------+
| Richard R.      | Thesis Advisor (M.D.,       | N |                     |
| Griffith        | Ph.D.) (1985-1988)          | I |                     |
|                 |                             | H |                     |
|                 |                             | p |                     |
|                 |                             | o |                     |
|                 |                             | s |                     |
|                 |                             | t |                     |
|                 |                             | - |                     |
|                 |                             | d |                     |
|                 |                             | o |                     |
|                 |                             | c |                     |
|                 |                             | t |                     |
|                 |                             | o |                     |
|                 |                             | r |                     |
|                 |                             | a |                     |
|                 |                             | l |                     |
|                 |                             | f |                     |
|                 |                             | e |                     |
|                 |                             | l |                     |
|                 |                             | l |                     |
|                 |                             | o |                     |
|                 |                             | w |                     |
|                 |                             | / |                     |
|                 |                             | P |                     |
|                 |                             | r |                     |
|                 |                             | i |                     |
|                 |                             | v |                     |
|                 |                             | a |                     |
|                 |                             | t |                     |
|                 |                             | e |                     |
|                 |                             | P |                     |
|                 |                             | r |                     |
|                 |                             | a |                     |
|                 |                             | c |                     |
|                 |                             | t |                     |
|                 |                             | i |                     |
|                 |                             | c |                     |
|                 |                             | e |                     |
|                 |                             |   |                     |
|                 |                             | A |                     |
|                 |                             | l |                     |
|                 |                             | l |                     |
|                 |                             | e |                     |
|                 |                             | r |                     |
|                 |                             | g |                     |
|                 |                             | y |                     |
|                 |                             | / |                     |
|                 |                             | I |                     |
|                 |                             | m |                     |
|                 |                             | m |                     |
|                 |                             | u |                     |
|                 |                             | n |                     |
|                 |                             | o |                     |
|                 |                             | l |                     |
|                 |                             | o |                     |
|                 |                             | g |                     |
|                 |                             | y |                     |
+-----------------+-----------------------------+---+---------------------+
| Kendrick A.     | Thesis Advisor (M.D.,       |   | Residency Univ.     |
| Shunk           | Ph.D.) 1989-1993            |   | Chicago/ Cardiology |
|                 |                             |   | Fellow Johns        |
|                 |                             |   | Hopkins Baltimore,  |
|                 |                             |   | MD                  |
+-----------------+-----------------------------+---+---------------------+
| Tharaknath Rao  | Thesis Advisor              | R |                     |
|                 |                             | e |                     |
|                 | Masters degree (1992-1994). | s |                     |
|                 |                             | i |                     |
|                 |                             | d |                     |
|                 |                             | e |                     |
|                 |                             | n |                     |
|                 |                             | c |                     |
|                 |                             | y |                     |
|                 |                             | B |                     |
|                 |                             | a |                     |
|                 |                             | y |                     |
|                 |                             | l |                     |
|                 |                             | o |                     |
|                 |                             | r |                     |
|                 |                             | C |                     |
|                 |                             | o |                     |
|                 |                             | l |                     |
|                 |                             | l |                     |
|                 |                             | e |                     |
|                 |                             | g |                     |
|                 |                             | e |                     |
|                 |                             | o |                     |
|                 |                             | f |                     |
|                 |                             | M |                     |
|                 |                             | e |                     |
|                 |                             | d |                     |
|                 |                             | i |                     |
|                 |                             | c |                     |
|                 |                             | i |                     |
|                 |                             | n |                     |
|                 |                             | e |                     |
|                 |                             |   |                     |
|                 |                             | H |                     |
|                 |                             | o |                     |
|                 |                             | u |                     |
|                 |                             | s |                     |
|                 |                             | t |                     |
|                 |                             | o |                     |
|                 |                             | n |                     |
|                 |                             | , |                     |
|                 |                             | T |                     |
|                 |                             | e |                     |
|                 |                             | x |                     |
|                 |                             | a |                     |
|                 |                             | s |                     |
+-----------------+-----------------------------+---+---------------------+
| Malabika Ghosh  | Thesis advisor Ph.D. degree | G |                     |
|                 |                             | l |                     |
|                 | 1994-1996                   | a |                     |
|                 |                             | d |                     |
|                 |                             | s |                     |
|                 |                             | t |                     |
|                 |                             | o |                     |
|                 |                             | n |                     |
|                 |                             | e |                     |
|                 |                             | R |                     |
|                 |                             | e |                     |
|                 |                             | s |                     |
|                 |                             | e |                     |
|                 |                             | a |                     |
|                 |                             | r |                     |
|                 |                             | c |                     |
|                 |                             | h |                     |
|                 |                             | I |                     |
|                 |                             | n |                     |
|                 |                             | s |                     |
|                 |                             | t |                     |
|                 |                             | , |                     |
|                 |                             | S |                     |
|                 |                             | a |                     |
|                 |                             | n |                     |
|                 |                             | F |                     |
|                 |                             | r |                     |
|                 |                             | a |                     |
|                 |                             | n |                     |
|                 |                             | c |                     |
|                 |                             | i |                     |
|                 |                             | s |                     |
|                 |                             | c |                     |
|                 |                             | o |                     |
|                 |                             | , |                     |
|                 |                             | C |                     |
|                 |                             | A |                     |
+-----------------+-----------------------------+---+---------------------+
| Daniel Atchley  | Thesis advisor, Ph.D.       | M |                     |
|                 | degree                      | a |                     |
|                 |                             | j |                     |
|                 | 1998-2002                   | o |                     |
|                 |                             | r |                     |
|                 |                             | , |                     |
|                 |                             | U |                     |
|                 |                             | S |                     |
|                 |                             | A |                     |
|                 |                             | i |                     |
|                 |                             | r |                     |
|                 |                             | F |                     |
|                 |                             | o |                     |
|                 |                             | r |                     |
|                 |                             | c |                     |
|                 |                             | e |                     |
+-----------------+-----------------------------+---+---------------------+
| Silvana Vielma  | Thesis advisor, Ph.D.       | A |                     |
|                 | degree                      | s |                     |
|                 |                             | s |                     |
|                 | 1999-2002                   | o |                     |
|                 |                             | c |                     |
|                 |                             | i |                     |
|                 |                             | a |                     |
|                 |                             | t |                     |
|                 |                             | e |                     |
|                 |                             | P |                     |
|                 |                             | r |                     |
|                 |                             | o |                     |
|                 |                             | f |                     |
|                 |                             | e |                     |
|                 |                             | s |                     |
|                 |                             | s |                     |
|                 |                             | o |                     |
|                 |                             | r |                     |
|                 |                             | U |                     |
|                 |                             | n |                     |
|                 |                             | i |                     |
|                 |                             | v |                     |
|                 |                             | e |                     |
|                 |                             | r |                     |
|                 |                             | s |                     |
|                 |                             | i |                     |
|                 |                             | t |                     |
|                 |                             | y |                     |
|                 |                             | o |                     |
|                 |                             | f |                     |
|                 |                             | M |                     |
|                 |                             | e |                     |
|                 |                             | r |                     |
|                 |                             | i |                     |
|                 |                             | d |                     |
|                 |                             | a |                     |
|                 |                             | , |                     |
|                 |                             | V |                     |
|                 |                             | e |                     |
|                 |                             | n |                     |
|                 |                             | e |                     |
|                 |                             | z |                     |
|                 |                             | u |                     |
|                 |                             | e |                     |
|                 |                             | l |                     |
|                 |                             | a |                     |
+-----------------+-----------------------------+---+---------------------+
| Miran Jaffa     | Thesis co-advisor, PhD      |   |                     |
|                 | degree                      |   |                     |
|                 |                             |   |                     |
|                 | 2004-                       |   |                     |
+-----------------+-----------------------------+---+---------------------+

# 

# Member of Advisory Committee of Graduate Students 

James K. Fleming (Member)

William Kephart (Member)

Jami J. Sons Page (Member

Leena Pravina Amarnath (Member)

##### 

##### RESEARCH Trainees and Visiting Scientists

+-----------------------+-----------------------+---------------------+
| ###### Name           | [Status]{.underline}  | ####                |
|                       |                       | ## Present Position |
+-----------------------+-----------------------+---------------------+
| Lillian Harstine,     | Post-doctoral fellow  | Private Practice    |
| M.D.                  |                       | Endocrinology       |
|                       | 1981-82               |                     |
+-----------------------+-----------------------+---------------------+
| David Mordes, M.D.    | Post-doctoral fellow  | Private Practice    |
|                       |                       | Endocrinology       |
|                       | 1982-83               |                     |
+-----------------------+-----------------------+---------------------+
| Robert Mountcastle,   | Post-doctoral fellow  | Private Practice    |
| M.D.                  |                       | Endocrinology       |
|                       | 1983-84               |                     |
+-----------------------+-----------------------+---------------------+
| Timothy J. Lyons,     | Post-doctoral fellow  | Chief of            |
| M.D.                  |                       | Endocrinology       |
|                       | 1984-86               | University of       |
|                       |                       | Oklahoma            |
|                       |                       |                     |
|                       |                       | Oklahoma City, OK   |
+-----------------------+-----------------------+---------------------+
| Jun Watanabe, M.D.    | Post-doctoral fellow  | Associate Professor |
|                       |                       | Kyushu University   |
|                       | 1986-88               | Fukuoka, Japan      |
+-----------------------+-----------------------+---------------------+
| Christoph Gisinger,   | Post-doctoral fellow  | Professor of        |
| M.D.                  |                       | Medicine Univ of    |
|                       | 1988-90               | Vienna, Austria     |
+-----------------------+-----------------------+---------------------+
| Rudolph Jokl, M.D.    | Post-doctoral fellow  | Private Practice,   |
|                       |                       | Assist Prof         |
|                       | 1991                  |                     |
|                       |                       | Endocrinology, MUSC |
+-----------------------+-----------------------+---------------------+
| Alicia Jenkins, M.D.  | Post-doctoral fellow  | Senior Lecturer     |
|                       |                       | Melbourne           |
|                       | 1993                  | University          |
|                       |                       |                     |
|                       |                       | Melbourne,          |
|                       |                       | Australia           |
+-----------------------+-----------------------+---------------------+
| Marina Mironova, M.D. | Post-doctoral fellow  | East Carolina       |
|                       |                       | Univ.-Int Med       |
|                       | 1994-2000             | Residency           |
+-----------------------+-----------------------+---------------------+
| Akira Takei, M.D.     | Post-doctoral fellow  | Assistant Professor |
|                       |                       | Kyushu University   |
|                       | 1996-98               | Fukuoka, Japan      |
+-----------------------+-----------------------+---------------------+
| Sinikka Koskinen, M.D | Post-doctoral fellow  | Staff Physician     |
| \*                    |                       |                     |
|                       | 1996-1999             | University of       |
|                       |                       | Helsinki.           |
+-----------------------+-----------------------+---------------------+
| Sumita Bandyopadhyay, | Post-doctoral fellow  | Post-doctoral       |
| Ph.D.                 |                       | fellow              |
|                       | 1998-2000             |                     |
|                       |                       | Medical Univ of SC  |
|                       |                       |                     |
|                       |                       | Charleston, SC      |
+-----------------------+-----------------------+---------------------+
| Mitsunori Masakado,   | Post-doctoral fellow  | Assistant           |
| MD                    |                       | Professor,          |
|                       | 2000-2002             |                     |
|                       |                       | Kyushu University   |
|                       |                       | Fukuoka, Japan      |
+-----------------------+-----------------------+---------------------+
| Pavel Kraml, MD\*\*   | Visiting Scientist    | Associate Professor |
|                       | 2002-present          | Charles University  |
|                       |                       |                     |
|                       | Fulbright Scholar     | Prague, Czech       |
|                       |                       | Republic            |
+-----------------------+-----------------------+---------------------+
| Silvana Vielma, MD.   | Post-doctoral Fellow  | Associate           |
| PhD\*\*               | 2002-2003             | Professor, Univ     |
|                       |                       | Merida,Venezuela    |
+-----------------------+-----------------------+---------------------+
| Ja-Ran Ku, MD         | Post-doctoral fellow  | Director Div.       |
|                       | 2003-2004             | Endocrinology       |
|                       |                       |                     |
|                       |                       | Dept Medicine,      |
|                       |                       | Trinity Hospital,   |
|                       |                       | Daegu, Korea        |
+-----------------------+-----------------------+---------------------+
| Lynn Poole,MD, PhD    | Post-doctoral fellow  | Residency in        |
|                       | 2003-present          | Harvard Medical     |
|                       |                       | School              |
+-----------------------+-----------------------+---------------------+
| Alena Nareika, MD     | Post-doctoral fellow  | Post-doctoral       |
|                       | 2003-2005             | fellow MUSC         |
+-----------------------+-----------------------+---------------------+
| Antonio Saad, MD      | Post-doctoral fellow  | > Residency,        |
|                       | 2004-2007             | > General Surgery,  |
|                       |                       | > USC/LAC           |
|                       |                       |                     |
|                       |                       | USA                 |
+-----------------------+-----------------------+---------------------+
| Souzan Abdel-Razik,   | Post-doctoral fellow  |                     |
| MD                    | 2008-                 |                     |
+-----------------------+-----------------------+---------------------+

# 

-   JDF postdoctoral fellowship award, \$33,000/year, 7/1997-6/30/99

> \*\* Fullbright Scholar

# Research Advisor for Undergraduate Students (Summer Projects)

Richard Davis, Medical University of South Carolina (1979)

Soyun Han, Goucher College, Maryland (1980)

William J. Lawing, Chapel Hill, North Carolina (1984)

Carolyn Cray, Rollins College, Florida (1985)

Cynthia Collie, Medical University of South Carolina (1985)

Anne Kulze, Medical University of South Carolina (1986)

Andrea Williams, Medical University of South Carolina (1987)

E.J. Prijoles, SC Governor\'s School for Science and Mathematics (1992)

Greg Niemer, Medical Student, Medical University of South Carolina
(1992)

Christina Altman, College of Charleston, Charleston, SC (1993, 1994,
1995)

Nafees Bin Zafar, Academic Magnet High School (1994, 1995). Won first
place in the 1999-2000 SC Junior Science and Humanities Symposium,
Columbia, SC (12/95)

Rachel Rackley, State of SC Governor\'s School for Sciences and
Mathematics (1996). Won first place in the 1999-2000 SC Junior Science
and Humanities Symposium, Columbia, SC (12/96)

Nathan Nussbaum, State of SC Governor\'s School for Sciences and
Mathematics (1997)

Andrew Fleming, College of Charleston (1998)

Kevin Huang, Ohio State University (1998)

Michael Wertheimer, University of Colorado (1998)

Antuan Crawford, Academic Magnet High School (1998)

Shan Wu, State of SC Governor\'s School for Sciences and Mathematics
(1999). Won first place in the 1999-2000 SC Junior Science and
Humanities Symposium, Columbia, SC (12/99)

Octavia Smalls, Claflin College (1999)

Leslie Fielder, South Carolina Governor's School for Science and
Mathematics (2000)

Fran Anderson, Darmouth College (2000)

Gregor Krings , Medical Scientist Program, Medical University of South
Carolina (2000, 2001)

Adam Gorod, Porter-Gaud High School (2001). Won 2nd place on MUSC
Research Day

David McCarty, South Carolina Governor's School for Science and
Mathematics (2001)

Ryan Wilson, South Carolina Governor's School for Science and
Mathematics (2002)

Jeffrey Abrams, South Carolina Governor's School for Science and
Mathematics (2002)

Meriana Martin, Dental School, Medical University of SC, Charleston, SC
(2002)

Arlene Mendez, University of Puerto Rico, Puerto Rico (2002). Won 1st
place on MUSC Research Day.

Katrina Hering, Medical University of SC (2004)

Edward Crosswell, Medical University of SC (2006)

> **OTHER TEACHING ACTIVITIES**
>
> **For Medical Students**
>
> 1982-1987 Introduction to Clinical Reasoning, sophomore medical
> students,
>
> *Small Group Preceptor*
>
> 1984-2000 Pathology and Laboratory Medicine Course, sophomore medical
> students
>
> > *Lecturer and Small Group Preceptor*
>
> 1984-Present Physical Diagnosis Course, sophomore medical students
>
> 1986-2000 Clinical Nutrition Course, junior medical students
>
> > *Course Director, Lecturer and Small Group Preceptor*
>
> 1999-Present GCRC/Cardiovascular Risk Factor Management, Senior
> Elective
>
> 2000-2002 Nutrition in Health and Disease, Freshmen, sophomores and
> juniors
>
> *Course Director, Lecturer and Small Group preceptor*
>
> 2001-Present Course of Immunology and Infectious Diseases, sophomore
> medical students, *Lecturer*
>
> 2004-Present Seminars for MD/PhD students, MUSC, *Lecturer*
>
> 2005-Present Pathophysiology of Disease, Course for Physician
> assistant students, *Lecturer*
>
> **For Graduates and post-graduates**

1974, January Physiopathology Basis and Laboratory Detection of
Dysproteinemias, Ciudad Sanitaria Jose Antonio, Zaragoza, Spain,
*Lecturer*

1974, Mar/Apr II Basic Immunology Course, Gulbenkian Institute of
Science, Oeiras, Portugal, *Lecturer*

1979, October Management of Diabetes and Endocrine Disorders, Hilton
Head, South Carolina, *Lecturer*

1982 Lipid and Steroids, MCBP Program, Medical University of SC,
*Lecturer*

# 1991 38th Annual Postgraduate Course, American Diabetes Association, San Diego, California, *Lecturer*

# 1984-Present Research Conferences, Endocrine Rounds and Clinic Preceptorship for Endocrinology Fellows and Medicine Residents, MUSC

# 1990-Present Housestaff Core Lectures, MUSC

# 2002-2005 Advanced Course of Cardiology for Graduate students, MUSC, *Lecturer*

2006 Foundations in Biomedical Sciences (Core curriculum course of the
College of Graduate studies #701/702) MUSC

##### MEETINGS/SYMPOSIA/WORKSHOPS

1990, May 11 Management of Lipid Disorders, Charleston, South Carolina,
*Program Chair*

1991, Dec 7-8 Diabetes and Lipids Connection: Novel Approaches to its
Diagnosis and Treatment, Charleston, South Carolina, *Program Chair*

1992, Dec 12 Lipid Disorders - Strategies for Successful Treatment of
Women, Elderly, and Post-coronary Bypass Patients, Charleston, South
Carolina, *Program Chair*

1991, June 20 Satellite Symposium on Diabetes and Macrovascular
Complications, XIV International Diabetes Federation Congress,
Charleston, South Carolina, *Program Chair*

1992-2000 Southeast Annual Lipid Conferences, *Program Committee Member*

1994, Nov 12-13 Satellite Symposium on Diabetes and Macrovascular
Complications, XV International Diabetes Federation Congress, Osaka,
Japan, *Program Committee Member*

1997, Jan 10 Diagnosis and Management of Lipid Disorders in Diabetes,
Charleston, SC, *Program Committee Member*

1997, June 20 Satellite Symposium on Management of Lipid Disorders in
Diabetes,

> 57th Annual Meeting, American Diabetes Association, Boston,
> Massachusetts. *Moderator*

1997, June 21-24 57th Annual Meeting, American Diabetes, Association,
Boston, Massachusetts, *Program Committee*

1997, June 21-24 Relative importance of triglyceride-rich lipoproteins
and LDL on Macrovascular

> Disease, Council on Complications Discussion Session, 57th Annual
> Meeting, American Diabetes Association, Boston, Massachusetts,
> *Moderator*

1997, July 25-27 Satellite Symposium on Atherosclerotic Vascular Disease
in Diabetes, XVI International Diabetes Federation Congress, Helsinki,
Finland, *Program Committee Member*

1997, July 20-24 Hyperglycemia and Macrovascular Disease Symposium,

> 16th International Diabetes Federation Congress, Helsinki,
> Finland,*Chair*

1998, June 13-16 58th Annual Meeting, American Diabetes, Association,
Chicago, Illinois, *Program Committee Member*

1998, June 13-16 Targets and goals to reduce cardiovascular risk in
diabetes, Council on Complications Discussion Session, 58th Annual
Meeting, American Diabetes Association, Chicago, Illinois, *Moderator*

1998, June 13-16 Hyperglycemia and Macrovascular Disease Symposium, 58th
Annual Meeting, American Diabetes Association, Chicago, Illinois,
*Chair*

1999, June 19-22 Aggressive Lipid Management in the Diabetic Patient,
*Meet the Professor Sessions,* 59th Scientific Sessions, American
Diabetes Association, San Diego, California

1999, August 6-8 Southeast Lipid Association Second Annual Scientific
Meeting, Homestead, Hot Springs, Virginia *Program Chair*

1999, August 18 Diagnosis and Management of Lipid Disorders in Diabetes,
Charleston, SC, *Program Committee Member*.

2000, June 9-13 Use of Combination Therapy to Achieve Appropriate Lipid
and Blood Pressure Goals in the Diabetic Patient, *Meet-the-Professor
sessions* (shared with George Bakris, MD), 59th Scientific Sessions,
American Diabetes Association, San Antonio, Texas

2000, Nov 3-5 17th IDF Satellite Symposium on "Lipoproteins, Vascular
Biology and Macrovascular Disease in Diabetes", Cancun, Mexico, November
3-4, 2000, *Program Chair*

2001, Jan 18-20 Prevention VI: Diabetes and Cardiovascular Disease, Amer
Heart Assoc, Orlando

2003, Aug 24-29 Poster session on Oxidative stress in vascular disease,
18^th^ IDF congress, Paris France, *Moderator*

2006, Sept 22-24 15^th^ SouthEast Lipid Research Conference, Callaway
Gardens, Georgia, *Program Chair*

### Invited Presentations

## International

1\. Abnormal LDL Metabolism in Diabetes Mellitus, International Workshop
on Macrovascular Disease in Diabetes Mellitus: Pathogenesis and
Prevention, October 18-20, 1984, Garmisch, Germany.

2\. Macrovascular and Cardiovascular Complications of Diabetes,
International Symposium on Current Challenges and Directions in Diabetes
Research, Juvenile Diabetes Foundation International, November 1-16,
1985, Monte Carlo, Monaco.

3\. Metabolism of LDL and HDL in Cultured Cells, International Symposium
on Atherosclerosis in Diabetes Mellitus, June 1, 1986, Osaka, Japan.

4\. Métabolisme Dès Lipoproteines Au Cours Du Diabète Sucré, 28th
Journées de Diabétologie de L\'Hôtel Dieu, May 11-13,1987, Paris,
France.

5\. Hypercholesterolemia-Diagnostic Criteria, International Symposium of
Cholesterol and Cardiovascular Disease: Consensus Conference, February
19-20, 1988, Lisbon, Portugal.

6\. Pathogenesis of Arteriosclerosis- New Concepts, IV Latin Meeting on
Vascular Research, November 6-9,1988, Lisbon, Portugal.

7\. Virus and Arteriosclerosis, 4th Congress of EuroMedicine, November
8-12, 1988, Montpellier, France.

8\. Hyperlipoproteinemias and Arteriosclerosis, XI Portuguese Congress
of Cardiology, April 26-29, 1989, Funchal, Madeira.

9\. Immune Mechanisms in the Pathogenesis of Atherosclerosis, 5th
International Colloquium, Foundation de Recherche Sur l\'Atherosclerose,
March 14-16, 1990, Brussels, Belgium.

10\. Immune Mechanisms of Atherosclerosis in Diabetes Mellitus,
Satellite Symposium on Macrovascular Complications. XIV International
Diabetes Federation Congress, June 20-22, 1991. Charleston, South
Carolina

11\. The Role of Immune Mechanisms in the Pathogenesis of
Atherosclerosis in Diabetes Mellitus, XIV International Diabetes
Federation Congress, June 23-28, 1991, Washington, DC.

12\. Atherosclerosis and Auto-immunity in Diabetes, 1st International
Symposium on Diabetes and Atherosclerosis, September 8-10, 1991, Dublin,
Ireland.

13\. Immune Mediated Mechanisms of Atherosclerosis in Diabetes Mellitus,
9th International Symposium on Atherosclerosis, October 6-11, 1991,
Chicago, Illinois.

14\. Atherosclerosis and Immune Mechanisms, 26th Annual Scientific
Meeting of the European Society for Clinical Investigation, April 1-4,
1992, Vienna, Austria.

15\. Interactions Between Lipopolysaccharides and Serum Lipoproteins and
Their Possible Role in CHD, X Paavo Nurmi Symposium on Role of Infection
and Inflammation in Vascular Disease, August 27-29, 1992, Helsinki,
Finland.

16\. Immunology of Modified Lipoproteins, 2nd International Symposium on
Diabetes and Atherosclerosis, EASD Lipid Study Group, September 5-8,
1992, Karlovy Vary and Prague, Czechoslovakia.

17\. Interrelated Metabolism Imbalances Linked to Hyperglycemia-induced
Vascular Dysfunction, 4th International Symposium on Treatment of
Diabetes Mellitus, October 26-27, 1993, Nagoya, Japan.

18\. Dislipidemia and Atherosclerosis in Diabetes Mellitus: Cellular
Mechanisms and Clinical Implications, I Portuguese Congress of Diabetes,
February 25-26, 1994, Porto, Portugal.

19\. Immune-Mediated Mechanisms of Atherogenesis in Diabetes, 15th
International Diabetes Federation Meeting, November 6-11, 1994, Kobe,
Japan.

20\. Cytokines, Modified Lipoproteins and Arteriosclerosis in Diabetes
Mellitus, Diabetes and Macrovascular Complications Symposium, November
12-13, 1994, Osaka, Japan.

21\. Current Approaches to the Diagnosis and Treatment of Lipid
Disorders in Diabetes Mellitus, November 14, 1994, Fukuoka, Japan.

22\. Cytokines, Modified Lipoproteins and Atherosclerosis in NIDDM, XI
Paavo Nurmi Symposium on Diabetes and Atherosclerosis, September 15-20,
1995, Helsinki, Finland.

23\. Modified Lipoproteins and Atherosclerosis in Diabetes, Lipoprotein
Study Group Workshop, European Association for the Study of Diabetes
(EASD), March 20-22, 1997, Sorrento, Italy.

24\. Autoimmunity of Atherosclerosis, Center of Immunology, Universidad
de los Andes, April 25, 1997, Merida, Venezuela.

25\. Is Atherosclerosis an Immunological Disease?, Satellite symposium
on Atherosclerotic Vascular Disease in Diabetes, 16th IDF Congress, July
25-27, 1997, Lappeenranta, Finland.

26\. Modified Lipoproteins and Receptor Interactions, British
Hyperlipidemia Association Workshop, March 11, 1998, London, England.

27\. Immunological Aspects of Atherosclerosis and Modified Lipoproteins
and Endothelial Dysfunction, VI Meeting on Lipid Metabolism and Related
Pathology, November 22-25, 1998, Costa da Caparica, Portugal.

28\. Update on Lipid Therapy, XIV Venezuelan Congress of Medical
Sciences, March 27-29, 2000, Merida, Venezuela.

29\. Combination Therapy to Achieve Adequate Lipid and Blood Pressure
Goals on Diabetes Mellitus Patients, IV Paulista Congreso, Endocrinology
and Metabology, May 25-26, 2001, São Paulo, Brazil.

30\. Endothelial Dysfunction in Diabetes, IV Paulista Congreso,
Endocrinology and Metabology, May 25-26, 2001, São Paulo, Brazil.

31\. Antibodies Against Modified LDL and ox-LDL Immune Complexes as
Predictors of Diabetic Complications, IV Paulista Congreso,
Endocrinology and Metabology, May 25-26, 2001, São Paulo, Brazil

32. Hyperglycemia and insulin resistance in atherogenesis, International
    Congress of Diabetes, October 17-19, 2002, Buenos Aires, Argentina

33. Management of Cardiovascular Risk in Diabetes. What's new?
    Portuguese Congress of cardiology, April 28, 2003, Funchal, Madeira

34. Qualitative Modifications of Lipoproteins in Type 2 Diabetes,
    Symposium on Insulin Resistance and Type 2 diabetes, International
    Diabetes Federation Meeting, August 24-29, 2003, Paris, France

35. Development of capture assays for modified human LDL, 8^th^
    International Symposium on the Maillard reaction, August
    28-September 1^st^, 2004, Charleston, SC.

36. Treatment of Diabetic Dyslipidemias. 75^th^ European Atherosclerosis
    Society meeting, April 23-26, 2005. Prague, Czech Republic

######### [National and Regional]{.smallcaps}

######### *Invite*d *Research Presentations*

1\. HDL and CHD: The Lipid Hypothesis, Duke University School of
Medicine and University of North Carolina School of Medicine, June 4-5,
1981, Durham and Chapel Hill, North Carolina

2\. Immunochemical Determination of Human Apolipoproteins by Laser
Nephelometry, Workshop on Apolipoprotein Methods, NHLBI, NIH, September
21-22, 1982, Chevy Chase, Maryland.

3\. Pathophysiopathology of Lipoprotein Disorders, Cholesterol Education
Workshop of the SC Affiliate of the American Heart Association, March
19, 1988, Columbia, South Carolina.

4\. Lipid Disorders as CHD Risk Factors,Workshop on Cardiovascular Risk
Factors, SC Medical Association Annual Meeting, April 29-30, 1988,
Charleston, South Carolina.

5\. Interaction of Lipoproteins with Human Macrophages and Endothelial
Cells in Diabetes Mellitus, 23rd International Research Symposium,
American Diabetes Association, March 6-8, 1989, Hilton Head, South
Carolina.

6\. The Role of Insulin in Abnormalities of Lipoprotein Metabolism in
NIDDM Patients, Consensus Conference on the Role of Cardiovascular Risk
Factors in the Prevention and Treatment of Macrovascular Disease in
Diabetes, American Diabetes Association, May 10-12, 1989, Denver,
Colorado

7\. Lipoproteins and Immune Response in the Vascular Wall and their
Contribution to Atherosclerosis in Diabetes, International Symposium on
Diabetes, Vascular Risks and Gliclazide, June 28, 1991, Washington, DC

8\. Pathogenesis of Coronary and PeripheralVascular Disease in Diabetes
Mellitus, 7th Annual Regional Scientific Conference on Diabetes
Mellitus, May 21-24, 1992, Ponte Vedra Beach, Florida.

9\. Autoimmune Mechanisms of Atherosclerosis and Future Prospects for
Intervention, 9th Annual National Clinical Care Diabetes Conference:
Update on Treatment of Vascular Disease in Diabetes, September 18-20,
1992, Norfolk, Virginia.

10\. Role of Modified Lipoproteins in the Development of Arterial
Disease in Diabetes, 53rd Annual Meeting, American Diabetes Association,
June 12-15, 1993, Las Vegas, Nevada.

11\. Autoimmunity, Macrovascular Disease and Diabetes, Research Seminar,
East Carolina University, January 21, 1994, Greenville, North Carolina.

12\. Heart Disease in Women, HCA Center for Research Education, May 6-7,
1994, Nashville, Tennessee.

13\. Coronary Heart Disease Risk Factors and Mechanisms of Atherogenesis
in Diabetes Mellitus: Clinical Implications, Medical Grand Rounds,
Medical College of Georgia, December 16, 1994, Augusta, Georgia.

14\. An Integrated View of the Role of Modified Lipoproteins in the
Development of Atherosclerosis in Diabetes, Endocrinology Grand Rounds,
Medical College of Georgia, December 16, 1994, Augusta, Georgia

15 Modified Lipoproteins, Auto-immunity and Atherosclerosis, University
of Pennsylvania, April 25, 1995, Pittsburgh, Pennsylvania.

16\. Cytokines and Adhesion Molecules, Research Seminar, Clinical
Pharmacology Center, April 26, 1995, University of Pennsylvania,
Pittsburgh, Pennsylvania

17\. Regulation of LDL-Receptor Expression in Human Macrophages
Activated by LDL-containing Immune Complexes, Research Seminar, Picower
Institute for Medical Research, March 26, 1996, Manhasset, New York

18\. Pathogenesis of Atherosclerosis in Diabetes, National Diabetes
Consultant Meeting, Ranchero Bernado Inn, June 6, 1997, San Diego,
California.

19\. Macrovascular Disease in Diabetes. New Concepts and Therapies,
Grand Rounds, Endocrinology and Metabolism Division, University of
Minnesota, October 9, 1997, Minneapolis, Minnesota.

20\. Regulation of LDL and Scavenger Receptor Expression in Human
Macrophages, Research Conference, University of Minnesota, October 9,
1997, Minneapolis, Minnesota.

21\. Inflammation and Atherogenesis, Grand Rounds in Medicine, Clemson
University, November 14, 1997, Clemson, South Carolina.

22\. Macrophage Activation and Macrovascular Disease, Biomedical Seminar
Series, Clemson University, November, 14, 1997, Clemson, South Carolina.

23\. Are Circulating Antibodies to LDL Relevant to the *in vivo* Risk of
Developing Coronary Artery Disease?, Council on Complications Current
Issues Session; American Diabetes Association 58th Scientific Sessions,
June 13-16, 1998, Chicago, Illinois.

24\. Activation and Gene Expression. Its Role in Atherosclerosis and
Plaque Rupture, Southeast Lipid Conference, September 10-13, 1998, Lake
Lanier, Georgia

25\. Lipids, Immunocomplexes and Inflammation of the Vascular Wall,
International Conference on Complications, Joslin Diabetes Center,
October 23-25, 1998, Boston, Massachusetts.

26\. Macrophage activation in plaque formation and rupture, Research
Seminar, Diabetes and Endocrinology Division, Columbia University,
October 19, 1999, New York, NY

27\. The Role of Immune and Inflammatory Processes in the Development of
Macrovascular Complications in Diabetes, University of Nebraska Medical
Center, April 17-18, 2001, Omaha, Nebraska

28\. The Edwin Bierman Award Lecture: Immune and Inflammatory Processes
in the Development of Macrovascular Complications in Diabetes Mellitus,
American Diabetes Association, 61st Annual Meeting,, June 21-24, 2001,
Philadelphia, Pennsylvania

29\. Metabolic Syndrome, Southeast Lipid Association Annual Scientific
Meeting. August 3-5, 2001, Charleston, South Carolina.

30\. Dyslipidemia and Macrovascular Disease in Diabetes. What's new?
Joslin Diabetes Center, March 11, 2002, Boston, MA.

31\. What's new in the Pathophysiology of Atherosclerosis? Changes and
Challenges in Cardiovascular Protection. Boston, MA, May 11, 2002

32. Physician and Scientist: Oil and Vinegar or Salad Dressing?,
    Southeast Lipid Association Annual Scientific Meeting, August 2-4,
    2002, Williamsburg, Virginia.

33. Cardiovascular Disease in Diabetes, Council Discussion on Are
    diabetic complications preventable? , 63 rd annual meeting of the
    American Diabetes Association , June 13-17, 2003 New Orleans,
    Louisiana

34. Insulin Resistance, Workshop on Diabetic Complications: Progress
    through animal models, sponsored by National Institute of Diabetes &
    Digestive & Kidney Diseases, National Heart, Lung and Blood
    Institute, National Institute of Neurological Disease and Stroke,
    National Eye Institute and Juvenile Diabetes Research Foundation,
    October 20-21, 2003, Washington DC.

35. Cardiovascular Risk and lipid management. Gender differences. 13^th^
    SouthEast Lipid Research Conference, Callaway Gardens, September
    23-26, 2004

36. Inflammation and Cardiovascular Disease in Diabetes. Cardiology
    Fellowship Lecture series, University of Minnesota, Jan 5, 2005

37. Lipoprotein Metabolism, Inflammation and Obesity, Obesity day at the
    West Carolina University, NC, October 30, 2007

38. Development and Progression of Diabetic Complications: Is the Immune
    system the main culprit? Kresge Eye institute, Wayne State
    University, Detroit, MI, April 9, 2008

####### Clinical Presentations

1\. Cholesterol, Hypertension and Arteriosclerosis, 12th Annual
Southeastern Conference on High Blood Pressure Control, October 22-24,
1986, Charleston, South Carolina.

2\. Lipids and Lipoproteins as Risk Factors in NIDDM - When to
Intervene, Council on Diabetes in Youth, American Diabetes Association
47th Annual Meeting, June 6-9, 1987, Indianapolis, Indiana.

3\. Cholesterol and CHD,\" Community Health Section Conference,
September 27-30, 1987, Savannah, Georgia.

4\. Hyperlipidemias: Diagnosis and Treatment, 39th Annual Assembly of
the South Carolina Academy of Family Physicians, December 3-5, 1987,
Hilton Head, South Carolina.

5\. Hyperlipidemias and Macrovascular disease in Diabetes: New
Directions in Diabetes Management, South Carolina and Georgia
Affiliates, American Diabetes Association, May 19-22, 1988, Hilton Head,
South Carolina

6\. Women, Hormones and Cardiovascular Disease, Symposium on Practical
Aspects of Hypertensive and Cholesterol Diseases, August 19-21, 1993,
Nashville, Tennessee

7\. Prevention of Cardiovascular Disease and Diabetes, Medical Grand
Rounds, Bowman Gray School of Medicine, September 7, 1993,
Winston-Salem, North Carolina

8\. Update in the Treatment of Hypercholesterolemia, Myrtle Beach
Medical Society, April 1994, Myrtle Beach, South Carolina

9\. Update in the Diagnosis and Management of Hypercholesterolemia,
Marion Memorial Hospital, May 23, 1994, Myrtle Beach, South Carolina.

10\. Recognition and Treatment of the High Risk Patient for
Cardiovascular Disease, Managing Health in the Aging, Southern Clinical
Neurological Society, September 26, 1996, Charleston, SC.

11\. New Advances in Lipid Management, Moody Air Force Base, April 4,
1997, Valdosta, Georgia.

12\. Lipid Management in Clinical Practice: Improving Patient Outcomes,
April 30, 1997, Greenville, South Carolina, sponsored by the
Professional Postgraduate Services.

13\. Advances in Lipid Therapy, Medical Education Programs, The
Woodlands, September 6, 1997, Summerville, South Carolina.

14\. Lipid Management in Clinical Practice: Improving Patient Outcomes,
Session Leader, October 8, 1997, LMCP Regional Dinner Conference,
Baltimore, Maryland.

15\. Lipid Management in Diabetes, EDIC Study Coordinators Meeting,
February 6, 1998, Charleston, South Carolina.

16\. Diagnosis, Prevention and Treatment of Hypertriglyceridemia,
Insulin Resistance Syndrome and Diabetic Dyslipidemia, LMCP CME District
Symposium, July 25, 1998, Destin, Florida.

17\. Management of Lipid Disorders, 4th Annual Diabetes Symposium for
Primary Health Care Professionals, October 1, 1998, Charleston Hilton
Hotel, Charleston, South Carolina.

18\. Diet and CAD Risk. The Role of Vitamins, Annual South Carolina
Dietetic Association, October 15-16,1998, Myrtle Beach, South Carolina.

19\. Rationale for Cholesterol Lowering, National Lipid Education
Council, November 14, 1998, Louisville, Kentucky.

20\. Hyperlipidemia in the VA Setting: Focusing the Attack. A Case-Based
Approach to Management, National Lipid Education Council, November 16,
1998, Chapel Hill, North Carolina

21\. Hyperlipidemia in the VA Setting: Focusing the Attack, CME Clinical
Conference, Professional Postgraduate Services, December 9, 1998,
Richmond, Virginia.

22\. Lipid Management in Clinical Practice: Improving Patient Outcomes,
National Lipid Education Council, January 12, 1999, Charlotte, North
Carolina.

23\. Lowering the Risk of CHD: Clinical Benefits of Aggressive LDL-C
Reduction, Dannemiller Memorial Foundation, October 6, 1999, West Palm
Beach.

24\. Lowering the Risk of CHD: Clinical Benefits of Aggressive LDL-C
Reduction, Dannemiller Memorial Foundation, October 12, 1999,
Charleston, SC.

25\. Lowering the Risk of CHD: Clinical Benefits of Aggressive LDL-C
Reduction, Dannemiller Memorial Foundation, October 26, 1999,
Roca-Baton, Florida.

26\. Lowering the Risk of CHD: Clinical Benefits of Aggressive LDL-C
Reduction, Dannemiller Memorial Foundation, December 2, 1999, Tampa,
Florida.

27\. Lipoproteins and cardiovascular risk in Diabetes, June 15, 2000,
Charleston Place, Charleston, South Carolina

28\. Strategies in the Management of Cardiovascular Risk in Diabetes,
New York, New York, June 25, 2000

39\. Updating Lipid Management for Primary Care Physicians, July 13,
2000, Naval Weapon Station, Charleston, South Carolina.

40\. Customizing Lipid Management According to the Patient's Profile,
August 22, 2000, Beaufort, South Carolina.

41\. Update in the Management of Lipid Disorders with Special Emphasis
on Diabetic Patients, September 15, 2000, Myrtle Beach, South Carolina.

27\. Reducing Cardiovascular Risks-Lipid Management in Diabetes,
Southern Medical Association Meeting, March 25-28, 2001, Destin, Florida

43\. Dyslipidemia and the Diabetic Patient, April 2, 2001, Medical
Views, Southern Vistas, Charleston, South Carolina.

44\. NECP-ATP-III guidelines and its clinical applications, June 15,
2001, Myrtle Beach, South Carolina

45\. The ATP-III Guidelines, Regional Advisory Meeting, 9/21-22,2001,
Atlanta , Georgia

46\. The need for intensive cholesterol lowering: a review of
lipoproteins, landmark clinical trials and patient issues, Changes and
Challenges in Cardiovascular Protection. May 11, 2002, Boston, MA

47\. The Evolving Lipid Management Paradigm, University of Tennessee
Cardiology Rounds, June 19,2002, Knoxville, Tennessee

48\. The need for intensive cholesterol lowering: a review of
lipoproteins, landmark clinical trials and patient issues, Changes and
Challenges in Cardiovascular Protection, June 29,2002 St Louis, Missouri

49\. The ATP-III evidence-based guidelines: what are the changes and the
rationale. Changes and Challenges in Cardiovascular Protection, May 11,
2002, Boston, MA

50\. Identifying and treating subgroups of high risk patients for CHD
and CVD. Changes and Challenges in Cardiovascular Protection, June 29,
2002, St Louis, Missouri

51\. Management of Lipid Disorders. The new ATP-III guidelines, Focus on
the female patient, Southern Medical Association, July 9, 2002, Kiawah
Island, SC.

52\. The Evolving Lipid Management Paradigm: Clinical Implications for
Practice. The Evolving Lipid Management Paradigm: Centers of Excellence.
Emory Conference Center, September 14, 2002, Atlanta, GA.

53. The Evolving Lipid Management Paradigm, East Jefferson General
    Hospital Cardiology Rounds, November 19,2002, Metairie, Louisiana

54. LDL-Apheresis-Beyond Drug Therapy-The principles and Therapeutic
    Applications, Workshop, SouthEast Lipid Association, 6^th^ Annual
    Meeting, August 22-24, 2003, Roca Baton, Florida.

55. Heart Disease in Women. Gender differences in Risk and Management.
    In "Achieving Success in Women's Healthcare. Early Detection and
    Treatment." May 12-13, 2005. Atlanta, GA

56. The Endocannabinoid system: a new target for the reduction of
    cardiovascular risk factors. The Metabolic Syndrome. Sponsored by
    the Endocrine Society, May 31 (Houston, Texas) and June 1 (San
    Antonio, Texas), 2006

57. Management of lipid cases: Diabetes Fall Symposium for Primary
    Health Care professionals, September 10-12, 2008, North Charleston,
    SC

### PEER-REVIEWED PUBLICATIONS 

## Manuscripts

## a. Published

1\. **Lopes MF**. "Chronic Broncho-Pulmonary Diseases and
Mucoviscidosis." *Medicina Universal,* 11:261-281, 1968 (Port.).

2\. **Lopes MF** and Levy ML. "About a Case of Cystic Fibrosis."
*Revista Portuguesa de Pediatria,* 31:238-245, 1968 (Port.).

3\. Virella G and **Lopes MF**. "The Immunoglobulins. IV. Monoclonal
Gammopathies." *Medicina Universal,* 12:23-28, 1969 (Port.).

4\. **Lopes MF**. "Pigeon Breeder\'s Disease." *0 Medico,* 55:795-799,
1970 (Port.)

5\. Virella G and **Lopes-Virella MF**. "Effects of Therapeutically
Useful Thiols (DL-penicillamine and Alpha-mercaptopropionylglycine) on
Immunoglobulins." *Clin Exp Immunol,* 7:85-107, 1970 (Port.).

6\. Virella G and **Lopes MF**. "Correlations Between Laboratorial
Studies, Diagnosis, Therapy and Prognosis of Monoclonal Gammopathies."
*Revista Portuguesa de Terapêutica Médica,* 4:190-200, 1970 (Port.).

7\. **Lopes-Virella MF**, Palma Carlos ML and Ducla Soares A. "Clinical
Trial of Alpha-Mercaptopropionylglycine (Tiolidon) in Rheumatoid
Arthritis." *Revista Portuguesa de Terapêutica Médica,* 6:23-27, 1972
(Port.).

8\. **Lopes-Virella MF**, Sequerra Amram S, Parreira F and Virella G.
"Serum Lipoprotein Electrophoresis, II-Polyacrylamide Gel
Electrophoresis." *0 Médico,* 69:496-500, 1973 (Port.).

9\. **Lopes-Virella MF**, Martins Prata M, Virella G and Ducla Soares A.
"Lipoproteins in the Nephrotic Syndrome." *0 Médico,* 70:153-155, 1974
(Port.).

10\. **Lopes-Virella MF**, Virella G, Parreira F and Sequerra Amram S.
"Comparative Analysis of Some Techniques for the Electrophoretic
Separation of Serum Lipoproteins." *Revista Clinica Española,*
133:195-204, 1974 (Span.).

11\. Virella G, Gervasio da Silva JJ, **Lopes-Virella MF** and Parreira
F. "Intracellular Light Chains in Peripheral Lymphocytes of a Patient
with Chronic Lymphatic Leukemia." *Sangre,* 20:456-466, 1975 (Span.).

12\. **Lopes-Virella MF**, Sarji K, Virella G and Colwell JA. "Platelet
Lipoproteins - A Comparative Study with Serum Lipoproteins." *Biochim
Biophys Acta,* 439(2):339-348, 1976.

13\. **Lopes-Virella MF** and Colwell JA. "Serum High Density
Lipoprotein in Diabetic Patients." *Lancet,* 1:1291-1292, 1976.

14\. **Lopes-Virella MF**, Stone P, Ellis S and Colwell JA. "Cholesterol
Determination in High Density Lipoproteins Separated by Three Different
Methods." *Clin Chem,* 23:882-884, 1977.

15\. Virella G, Monteiro JN, **Lopes-Virella MF**, Ducla Soares A and
Fudenberg HH. "Asyncronous Development of Two Monoclonal Proteins (IgM k
and g-1 Chains) in a Patient with Abdominal Lymphoma." *Cancer,*
39:2247-2253, 1977.

16\. **Lopes-Virella MF**, Stone P and Colwell JA. "Serum High Density
Lipoprotein in Diabetes." *Diabetologia,* 13:285-291, 1977.

17\. Virella G and **Lopes-Virella MF**. "New Approaches to the Study of
Proteinuria." *Clin Chem,* 23:1793-1794, 1977.

18\. **Lopes-Virella MF** and Colwell JA. "Tight Metabolic Control may
Normalize HDL and Check Macrovascular Disease in Diabetes." *Metab
Therapy,* 6:1-3, 1977.

19\. Virella G, **Lopes-Virella MF**, Levine J, Ogawa M and Gonzalez J.
"Idiopathic

Bence-Jones Proteinuria." *Acta Haematologica,* 60:269-279, 1978.

20\. **Lopes-Virella MF**, Virella G, Rosebrock G, Sagel J, Gonzalez J
and Colwell JA. "Early Diagnosis of Renal Malfunction in Diabetics:
Abnormal Proteinuria Revealed by Sodium Dodecyl Sulfate-polyacrylamide
Gel Electrophoresis." *Diabetologia,* 16:165-171, 1979.

21\. Virella G, Munoz J, **Lopes-Virella MF**, Ward B and Gadsden R.
"Rapid Immunochemical Determination of Free Hemoglobin in Plasma and
Urine with a Laser Nephelometer." *Clin Chem,* 25:497-499, 1979.

22\. **Lopes-Virella MF**, Virella G, DeBeukelaer M, Owens CJ and
Colwell JA. "Urinary High Density Lipoprotein in Minimal Change
Glomerular Disease and Chronic Glomerulopathies." *Clin Chim Acta,*
94:73-81, 1979.

23\. Colwell JA, Halushka PV, Sarji KE, **Lopes-Virella MF** and Sagel
J. "Vascular Disease in Diabetes. Pathophysiological Mechanisms and
Therapy." *Arch Intern Med,* 139:225-230, 1979.

24\. Sagel J, **Lopes-Virella MF**, Colwell JA and Levine JH. "Altered
High Density Lipoprotein Cholesterol (HDL-CHOL) in
Hypothalamic-Pituitary Disorders." *J Clin Endocrinol Metab,*
49:753-756, 1979.

25\. Gordon L, Mayfield RK, Levine JH, **Lopes-Virella MF**, Sagel J and
Buse MG. "Failure to Visualize Adrenal Gland in a Patient with Bilateral
Adrenal Hyperplasia." *J Nucl Med,* 21:49-51, 1980.

26\. **Lopes-Virella MF**, Adams K, O\'Dell R and Virella G. "Cold
Agglutinin Disease: A Case Complicated with an Episode of Acute Renal
Failure." *Clin Immunol Newsletter,* 1(9):1-4, 1980.

27\. **Lopes-Virella MF**, Virella G, Evans G, Malenkos SB and Colwell
JA. "Immunonephelometric Assay of Human Apolipoprotein AI." *Clin Chem*,
26:1205-1208, 1980.

28\. Virella G, Lopes-Virella M, and Estes G. "Nephelometric Assays in
Clinical Immunology." Microbiology by American Society of Microbiology,
1981:326-331.

29\. Colwell JA, **Lopes-Virella MF** and Halushka PV. "Pathogenesis of
Atherosclerosis in Diabetes Mellitus." *Diabetes Care,* 4:121-133, 1981.

30\. **Lopes-Virella MF**, Wohltmann J, Loadholt B and Buse MG. "Plasma
Lipid and Lipoprotein in Young Type I Diabetic Patients. Relationship
with Control." *Diabetologia,* 21:216-223, 1981.

31\. Virella G, Wohltmann H, Sagel J, **Lopes-Virella MF**, Kilpatrick
M, Philips C and Colwell JA. "Soluble Immunocomplexes in Patients with
Diabetes Mellitus, Detection and Pathological Significance."
*Diabetologia,* 21:184-191, 1981.

32\. **Lopes-Virella MF**, Sherer G, Lees AM, Wohltmann H, Mayfield R,
Sagel J, Leroy C and Colwell JA. "Surface Binding, Internalization and
Degradation by Cultured Human Fibroblasts of Low Density Lipoproteins
Isolated from Type I (Insulin-dependent) Diabetic Patients: Changes with
Metabolic Control." *Diabetologia,* 22:430-436, 1982.

33. **Lopes-Virella MF**, Wohltmann H, Mayfield RK, Loadholt CB and
    Colwell JA. "Effect of Metabolic Control on Lipid, Lipoprotein and
    Apolipoprotein Levels in 55 Insulin-dependent Diabetic Patients: A
    Longitudinal Study." *Diabetes,* 32:20-25, 1983.

34\. Virella G, **Lopes-Virella MF**, Shuller C, Sherwood T, Espinoza A,
Winocour P and Colwell JA. "Release of Platelet Activating Factor by
Polymorphonuclear Leukocytes Stimulated by Immune Complexes Bound to
Sepharose Particles in Human Erythrocytes." *Immunology,* 50:43-51,
1983.

35\. Colwell JA, Winocour PD, **Lopes-Virella MF** and Halushka PV. "New
Concepts About the Pathogenesis of Atherosclerosis in Diabetes
Mellitus." *Am J Med,* 75:67-80, 1983.

36\. Winocour PD, **Lopes-Virella MF**, Laimins M and Colwell JA.
"Time-Course of Changes *In Vitro* Platelet Function and Plasma von
Willebrand Factor Activity (VIII-R,WF) and Factor VIII Related Antigen
(VIII-R, Ag) in the Diabetic Rat." *J Lab Clin Med,* 102:795-804, 1983.

37\. Winocour PD, **Lopes-Virella MF**, Laimins M and Colwell JA. "The
Effect of Insulin Treatment in Streptozotocin-induced Diabetic Rats on
*In Vitro* Platelet Function and Plasma von Willebrand Factor Activity
(VIIIR:WF) and Factor VIII Related Antigen (VIIIR:Ag)." *Journal of
Laboratory and Clinical Medicine,* 106:319-325, 1985.

38\. **Lopes-Virella MF**. "Abnormal Metabolism of LDL in Diabetes
Mellitus." *Horm Metab Res,* 15(S):83-87, 1985.

39\. Colwell JA, **Lopes-Virella MF**, Mayfield R and Sens D (eds).
"Workshop on Insulin and Atherogenesis." *Metabolism* ,12 (S1):1-91,
1985.

40\. **Lopes-Virella MF**. "Circulating Elements." In "Workshop on
Insulin and Atherogenesis." *Metabolism,* 12 (S1):87-91, 1985.

41\. Mayfield RK, Halushka PV, Wohltmann HJ, **Lopes-Virella MF**,
Chambers JK, Loadholt C and Colwell JA. "Influence of Glycemic Control
on Platelet Function in Insulin-dependent Diabetic Patients."
*Diabetes,* 34:1127-1133, 1985.

42\. **Lopes-Virella MF**, Sherer G, Wohltmann H, Sens D and Colwell JA.
"Diabetic Lipoprotein Deficient Sera. Its Effect in LDL Uptake and
Degradation by Fibroblasts." *Metabolism,* 34:1079-1085, 1985.

43\. **Lopes-Virella MF** and Virella G. "Immunological and
Microbiological Factors in the Pathogenesis of Atherosclerosis." *Clin
Immunol Immunopathol,* 37:377-386, 1985.

44\. Lyons TJ, Patrick J, Baynes JW, Colwell JA and **Lopes-Virella
MF**. "Degree of Glycation of LDL in a Group of Type I Diabetic
Patients: Correlations with Other Parameters of Glycemic Control."
*Diabetologia*, 29:685-689, 1986.

45\. **Lopes-Virella MF** and Colwell JA. "Pharmacological Treatment of
Lipid Disorders in Diabetes Mellitus." *Diabetes/Metabolism Reviews,*
3:691-722, 1987.

46\. **Lopes-Virella MF**, Klein RL and Stevenson HC. "Low Density
Lipoprotein Metabolism in Human Monocyte-derived Macrophages Stimulated
with Microbial or Microbial-related Products." *Arteriosclerosis,*
7:176-184, 1987.

47\. Virella G and **Lopes-Virella MF**. "Infections and
Atherosclerosis." *Transplantation Proceedings,* 19:26-35, 1987.

48\. Lyons TJ, Klein RL, Baynes JW and **Lopes-Virella MF**.
"Stimulation of Cholesteryl Ester Synthesis in Human Monocyte-derived
Macrophages by Lipoproteins from Type I Diabetic Patients: The Influence
of Glycation of Low Density Lipoprotein." *Diabetologia,* 30:916-923,
1987.

49\. **Lopes-Virella MF**, Klein RL, Lyons TJ, Stevenson HC and Witztum
JL. "*In Vitro* Glucosylated LDL Enhances Cholesteryl Ester Synthesis
and Accumulation in Human Monocyte-derived Macrophages." *Diabetes,*
37:550-557, 1988.

50\. Griffith RL, Virella GT, Stevenson HC and **Lopes-Virella MF**.
"LDL Metabolism by Macrophages Activated with LDL Immune Complexes: A
Possible Mechanism of Foam Cell Formation." *Journal Experimental
Medicine,* 168: 1041-1059, 1988.

51\. Colwell JA and **Lopes-Virella MF**. "A Review of the Pathogenesis
of Large Vessel Disease in Diabetes Mellitus." *Am J Med*, 85
(S5A):113-118, 1988.

52\. Watanabe J, Wohltmann HJ, Klein RL, Colwell JA and **Lopes-Virella
MF**. "Enhancement of Platelet Aggregation by LDL Isolated from Patients
with Insulin-dependent Diabetes Mellitus." *Diabetes,* 37: 1652-1657,
1988.

53\. Marken PA, Weart CW, Carson DS, Gums JG and **Lopes-Virella MF**.
"Effects of Magnesium Oxide on the Lipid Profile of Healthy Volunteers."
*Atherosclerosis*,

77: 37-42, 1989.

54\. Klein RL, Lyons TJ and **Lopes-Virella MF**. "Interaction of VLDL
Isolated from Type I (Insulin-dependent) Diabetic Subjects with Human
Monocyte-Derived Macrophages." *Metabolism,* 38:1108-14, 1989.

55\. Vaughn M, Virella G and **Lopes-Virella MF**. "Diabetes,
Autoimmunity and Arteriosclerosis." *Clinical Immunology and
Immunopathology*, 52:414-420, 1989.

56\. Klein RL, Lyons TJ and **Lopes-Virella MF**. "Metabolism of Very
Low and Low Density Lipoproteins Isolated from Normolipidaemic Type 2
(Non-Insulin-Dependent) Diabetic Patients by Human Monocyte-derived
Macrophages." *Diabetologia*, 33:299-305, 1990.

57\. Gisinger C, Virella GT and **Lopes-Virella MF**. "Erythrocyte-Bound
Low Density Lipoprotein (LDL) Immune Complexes Lead to Cholesteryl Ester
Accumulation in Human Monocyte Derived Macrophages." *J. Clin. Immun.
and Immunopathology*, 59:37-52, 1991.

58\. **Lopes-Virella MF**, Griffith RL, Shunk KA and Virella G.
"Enhanced Uptake and Impaired Intracellular Metabolism of LDL Complexed
with Anti-LDL Antibodies.\" *Arteriosclerosis*, 11: 1356-1367, 1991.

59\. Virella G, Fourspring K, Hyman B, Haskill-Stroud R, Long L, Virella
I, La Via M, Gross AJ, Oexmann MJ and **Lopes-Virella MF**.
"Immunosuppressive Effects of Fish Oil in Normal Human Volunteers:
Correlation with the *In Vitro* Effects of Eicosapentanoic Acid on Human
Lymphocytes." *Clinical Immunology and Immunopathology,* 61:161-176,
1991.

60\. **Lopes-Virella MF** and Virella G. "Lipoproteins and Immune
Response in the Vascular Wall and their Contribution to Atherosclerosis
in Diabetes." *Metabolism,* 41:11-15,1992.

61\. Klein RL, Wohltmann HJ and **Lopes-Virella MF**. "Influence of
Glycemic Control on the Interaction of Very Low and Low Density
Lipoproteins Isolated From Type 1 (Insulin-dependent) Diabetic Patients
With Human Monocyte-Derived Macrophages." *Diabetes*, 41: 1301-1307,
1992.

62\. **Lopes-Virella MF** and Virella G. "Immune Mechanisms of
Atherosclerosis in Diabetes Mellitus." *Diabetes*, 41: 86-91, 1992.

63\. Gisinger C and **Lopes-Virella MF**. "Lipoprotein Immune Complexes
and Diabetic Vascular Complications." *Diabetes*, 41: 92-96, 1992.

64\. Virella G, Virella I, Leman RB, Pryor MB and **Lopes-Virella MF**.
"Anti-oxidized LDL

Antibodies in Patients with Coronary Heart Disease and Normal Healthy
Volunteers." *Int. J. Clin. Lab. Res.,* 23:95-101, 1993.

65\. **Lopes-Virella MF**, Jokl R and Colwell JA. "Rheology and Clotting
Factors in Diabetes Mellitus." SM Marshall, PD Home, KGMM Alberti and L
Krall eds, Elsevier Science Publishers, *Diabetes Annual* 7: 83-106,
1993.

66\. **Lopes-Virella MF**. "Interactions Between Bacterial
Lipopolysaccharides and Serum Lipoproteins and their Possible Role in
Coronary Heart Disease." *European Heart Journal,*. 14 (K): 118-124,
1993.

67\. Klein RL and **Lopes-Virella MF**. "Metabolism by Human Endothelial
Cells of Very Low Density Lipoprotein Subfractions Isolated from Type I
(Insulin-dependent) Diabetic Patients." *Diabetologia,* 36: 258-264,
1993.

68\. Lyons TJ, **Lopes-Virella MF** and Baynes JW. "Glycation, Oxidation
and Glycoxidation in the Pathogenesis of Atherosclerosis in Diabetes."
*Modern Medicine*, 61:4-6, 1993.

69\. **Lopes-Virella MF**. "Peripheral Vascular Disease." Marshall, PD
Home, KGMM Alberti and LP Krall eds, Elsevier Science Publishers,
*Diabetes Annual* 8: 365-387, 1994.

70\. Jokl R, Laimins M, Klein RL, Lyons TJ, **Lopes-Virella MF** and
Colwell JA. "Platelet Plasminogen Activator Inhibitor 1 in Patients with
Type II Diabetes." *Diabetes Care*, 17: 818-823, 1994.

71\. **Lopes-Virella MF** and Virella G. "Atherosclerosis and
Autoimmunity." *Clinical Immunology and Immunopathology*, 73:155-167,
1994.

72\. Virella G, Mironova M and **Lopes-Virella MF**. "Assay of
Anti-Modified LDL Antibodies." *Clinical Chemistry*, 41:324-325, 1995.

73\. Virella G, Muñoz José F, Galbraith Gillian MP, Gisinger, C,
Chassereau C and **Lopes-Virella MF**. "Activation of Human
Monocyte-Derived Macrophages by Immune Complexes Containing Low Density
Lipoprotein." *Clin. Immunology and Immunopathology,* 75:179-189, 1995.

74\. Klein RL, Laimins M and **Lopes-Virella MF**. "Isolation,
Characterization and Metabolism of the Glycated and Non-Glycated
Subfractions of Low Density Lipoproteins Isolated From Type I Diabetic
Patients and Non-Diabetic Subjects." *Diabetes,* 44:1093-1098, 1995.

75\. Jokl R, Klein RL, **Lopes-Virella MF** and Colwell JA. "Release of
Platelet Plasminogen Activator Inhibitor 1 in Whole Blood is Increased
in Patients with Type II Diabetes." *Diabetes Care,* 18:1150-1155, 1995.

76\. **Lopes-Virella MF** and Virella G. "Cytokines, Modified
Lipoproteins and Arteriosclerosis in Diabetes Mellitus." *Diabetes*, 45:
40-44, 1996.

77\. **Lopes-Virella MF**, Klein RL and Virella G. "Modification of
Lipoproteins in Diabetes." *Diabetes/Metabolism Reviews,* 12:69-90,
1996.

78\. Mironova M, **Lopes-Virella MF** and Virella G. "Isolation and
Characterization of Human Anti-oxidized LDL Auto-antibodies."
*Arteriosclerosis, Thrombosis and Vascular Biology*, 16:222-229, 1996.

79\. Jenkins AJ, Klein RL, Chassereau CH, Hermayer KL and
**Lopes-Virella MF**. "LDL from Patients with Well Controlled IDDM is
not More Susceptible to *In Vitro* Oxidation." *Diabetes,* 45:762-767,
1996.

80\. **Lopes-Virella MF** and Virella G. "Modified Lipoproteins,
Cytokines and Macrovascular Disease in Non-insulin Dependent Diabetes
Mellitus." *Annals of Medicine,* 28:347-354, 1996.

81\. Huang Y, Ghosh MJ and **Lopes-Virella MF**. "Transcriptional and
Post-transcriptional Regulation of LDL Receptor Gene Expression in
PMA-treated THP-1 Cells by LDL-Containing Immune Complexes." *Journal of
Lipid Research,* 38:110-120, 1997.

82\. **Lopes-Virella MF**, Mironova M and Virella G. "LDL-IC and
Atherosclerosis in Diabetes Mellitus." *Diabetes Reviews*, 5:410-424
1997.

83\. Mironova M, Virella G, Virella-Lowell I and **Lopes-Virella MF**.
"Anti-modified LDL Antibodies and LDL-Containing Immune Complexes in
Well-controlled IDDM Patients and Healthy Controls." *Clinical
Immunology and Immunopathology*, 85:73-82 1997.

84\. **Lopes-Virella MF**, BinZafar N, Rackley S, Takei A, LaVia M and
Virella G. "The Uptake of LDL-IC by Human Macrophages: Predominant
Involvement of the FcγR I." *Atherosclerosis*, 135:161-170, 1997.

85\. **Lopes-Virella MF** and Virella G. "The Immunology of
Atherosclerosis." SM Marshall, PD Home and RA Rizza eds, Elsevier
Science Publishers, *Diabetes Annual* 11: 81-95, 1998.

86\. Koskinen S, Enockson C, **Lopes-Virella MF** and Virella G.
"Preparation of a Human Standard for Determination of the Levels of
Antibodies to Oxidatively Modified Low-Density Lipoproteins." *Clinical
and Diagnostic Laboratory Immunology*, 5:817-822, 1998.

87\. Willi SM, O'Rear D, Garvey WT, Colwell JA, Buse M, Jaffa A,
**Lopes-Virella MF**, Wood D, Mayfield R, Wallace P, Hernmayer KL,
Jenkins AJ, Lyons T and Mayer Davis E. "Diabetes Research in South
Carolina." *Journal of South Carolina Medical Association* 94:502-508,
1998.

88\. Huang Y, Ayad J, Koskinen S, Takei A and **Lopes-Virella MF**.
"Oxidized LDL-Containing Immune Complexes Induce Fc Gamma Receptor
I-Mediated Mitogen-Activated Protein Kinase Activation in THP-1
Macrophages." *Arteriosclerosis , Thrombosis and Vascular Biology*,
19:1600-1607, 1999.

89\. Islam S, Gutin B, Treiber F, Hobbs G, Kamboh MI and **Lopes-Virella
MF**. "Association of Apo(a) Phenotypes and Oxidized LDL-immune Complex
in Children." *Archives of Pediatrics & Adolescent Medicine*, 153:57-62,
1999.

90\. **Lopes-Virella MF**, Virella G, Orchard TJ, Koskinen S, Evans RW,
Becker D and

> Forrest K Y-Z. "Anti-oxidized LDL Antibodies and LDL-containing Immune
> Complexes as Risk Factors for Coronary Heart Disease in Diabetes
> Mellitus." *Clinical Immunology* 90:165-172, 1999.

91\. Orchard TJ, Forrest K Y-Z, Becker DJ, Virella G and **Lopes-Virella
MF**. "Antibodies

> to Oxidized LDL Predict CAD in Type I Diabetes: A Nested Case Control
> Study from the Pittsburgh Epidemiology of Diabetes Complications
> Study." *Diabetes*, 48:1454-58,1999.

92\. Huang Y, Mironova M and **Lopes-Virella MF**: "Oxidized LDL
Stimulates Matrix

> Metalloproteinase 1 Expression in Human Vascular Endothelial Cells."
> *Arteriosclerosis, Thrombosis and Vascular Biology*, 19:
> 2640-2647,1999.

93\. **Lopes-Virella,MF**, Koskinen S, Mironova M, Horne D, Klein R,
Chassereau C, Enockson C and Virella G: The preparation of
copper-oxidized LDL for the measurement of oxidized LDL antibodies by
EIA, *Atherosclerosis*, 152:107-115, 2000.

94\. Fu Y, Luo N and **Lopes-Virella, MF**. "Oxidized LDL Induces the
Expression of Adipocyte Binding Protein (ALBP/apz) MRNA and Protein in
Human THP-1 Macrophages, *Journal of Lipid Research*, 41(12):2017-2023,
2000.

95\. Mironova M, Klein R, Chassereau C, Virella G and **Lopes-Virella
MF**. \"Anti-Modified LDL Antibodies and LDL-Containing Immune
Complexes, and Susceptibility of LDL to In Vitro Oxidation in Patients
with Type 2 Diabetes.\" *Diabetes*, 49:1033-1041, 2000.

96\. Virella G, Koskinen S, Krings G, Onorato J.M., Thorpe S.R. and
**Lopes-Virella MF**. Immunochemical Characterization of Purified Human
Oxidized Low-Density Lipoprotein Antibodies. *Clinical Immunology,*
95:134-144, 2000*.*

97\. Huang Y, Fleming AY, Wu S, Virella G and **Lopes-Virella MF**.
"Fc-γ Cross-Linking by Immune Complexes Induces Matrix
Metalloproteinase-1 in U937 Cells via Mitogen-Activated Protein
Kinase.", *Arteriosclerosis, Thrombosis and Vascular Biology*,
20:2533-2538, 2000.

98\. Thomas JC, **Lopes-Virella, MF**, Del Bene, VE,Cerveny, JD, Taylor,
KB, McWhorter,

> LS and Bultemeier, NC: Use of Fenofibrate in the Management of
> Protease Inhibitor-Associated Lipid Abnormalities. *Pharmacotherapy*
> 20(6): 727-734, 2000.

99\. Huang Y, Song L, Wu S, Fan F and **Lopes-Virella, MF**. "Oxidized
LDL differentially

> regulates MMP-1 and TIMP-1 Expression in Vascular Endothelial Cells,
> *Atherosclerosis*, 156:119-125, 2001.

100\. Takei, A, Huang Y and **Lopes-Virella MF**. "Expression of
adhesion molecules by human endothelial cells exposed to oxidized low
density lipoprotein\" *Atherosclerosis*., 154:79-86, 2001.

101\. Klein R, Ascensão JL, Mironova M, Huang Y, **Lopes-Virella, MF**,
"Effect of Inflammatory Cytokines on the Metabolism of LDL By Human
Vascular Endothelial Cells. *Metabolism*, 50:99-106, 2001.

102\. Song L, Xu M, **Lopes-Virella MF** and Huang, Y. "Quercetin
Inhibits Matrix Metalloproteinase-1 Expression in Human Vascular
Endothelial Cells through Extracellular Signal-Regulated Kinase.
*Archives of Biochemistry and Biophysics,* 391:72-78, 2001

103\. Fu Y, Luo N, **Lopes-Virella MF**. Upregulation of interleukin-8
expression by prostaglandin D2 metabolite 15-deoxy-delta12, 14
prostaglandin J2 (15d-PGJ2) in human THP-1 macrophages.
*Atherosclerosis*, 160:11-20, 2002

104. Anderson F, Game B, Atchley D, Xu M, **Lopes-Virella M**, Huang Y.
     "IFN-γ Pretreatment Augments Immune Complex-Induced Matrix
     Metalloproteinase-1 Expression in U937 Histiocytes". *Clinical
     Immunol.* 102:200-207, 2002.

105. Fu Y, Luo N. **Lopes-Virella MF**, Garvet WT. The adipocyte lipid
     binding protein (ALBP/aP2) gene facilitates foam cell formation in
     human macrophages. Atherosclerosis 165: 259-69, 2002

106\. Virella G, Atchley D, Koskinen S, Zheng D, **Lopes-Virella MF**
and the DCCT/EDIC Research Group. "Pro-atherogenic and pro-inflammatory
properties of immune complexes prepared with purified human
oxLDLantibodies and human oxLDL". *Clinical Immunology*, 105:81-92,
2002.

107\. Vielma S, Gorod AJ, Virella G and **Lopes-Virella, MF**.
"Chlamydophila Pneumoniae infection of human aortic endothelial cells
induces the expression of Fcγ Receptor II (FcγRII). *Clinical
Immunology*, 104:265-273, 2002.

108\. Atchley D, **Lopes-Virella** MF, Zheng D, Virella G and the
DCCT/EDIC Research Group. Oxidized LDL-anti-oxidized LDL immune
complexes and diabetic nephropathy. *Diabetologia*, 45:1562-1571, 2002

109\. Eckel RH, Wassef M, Chait A, Sobel B, Barrett E, King G,
**Lopes-Virella M**, Reusch J, Ruderman N, Steiner G and Vlassara H:
Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing
Group II: pathogenesis of atherosclerosis in diabetes, *Circulation*
105: 138-143,2002

110\. Virella G, Thorpe, S, Alderson,NL, Stephan, E, Atchley D, Wagner,
F and **Lopes-Virella MF** and the DCCT/EDIC Research Group. Auto-immune
response to advanced glycation end-products of human low density
lipoprotein. *Journal of Lipid Research*, 44, 487-493, 2003

111\. Virella G. and **Lopes-Virella,MF**: Humoral immunity and
Atherosclerosis, *Nature Medicine*, 9:243-244, 2003

112. **Lopes-Virella MF** and G. Virella : The role of immune and
     inflammatory processes in the development of macrovascular disease
     in diabetes. *Frontiers in Bioscience*, 8: s750-768, 2003

113. Vielma SA, Kreggs G and **Lopes-Virella MF**: *Chamydophila
     pneumoniae* induces ICAM-1 Expression in human aortic endothelial
     cells via Protein Kinase C--dependent activation of Nuclear Factor
     κ-B: *Circulation Research* 92:1130-7,2003

114. Fu Y, Huang Y, Bandyopadhyay s, Virella G and **Lopes-Virella MF**:
     LDL immune complexes stimulate low density lipoprotein receptor
     expression in U937 histiocytes via extracellular signal-regulated
     kinase and AP-1. *Journal of Lipid Research,* 44:1315-21,2003

115. VirellaG and **Lopes-Virella MF**: Lipoprotein Autoantibodies:
     measurement and significance. *Clinical and Diagnostic Laboratory
     Immunology,* 10:499-505,2003

116. Game B, Xu M, **Lopes-Virella MF** and Huang Y: Regulation of MMP-1
     expression in vascular endothelial cells by insulin sensitizing
     thiazolidinediones, *Atherosclerosis,* 169:235-243, 2003.

117. **Lopes-Virella MF,** Mironova M, Stephan E, Durazo-Arvizu R,
     Virella G: The role of Simvastatin as an immunomodulator in Type 2
     Diabetes, *Diabetes Care*, 27: 908-13, 2004

118. Vielma, SA, Mironova M. Ku J-R, **Lopes-Virella MF**: Oxidized LDL
     further enhances expression of adhesion molecules in *Chlamydophila
     pneumoniae*--infected endothelial cells, *J. Lipid Res*. 45:
     873-80, 2004

119. Virella, G, Thorpe SR, Alderson N, Derrick MB, Rhett M , Chassereau
     C and **Lopes-Virella MF**: Definition of the immunogenic forms of
     modified human LDL recognized by human auto-antibodies and by
     rabbit hyperimmune antibodies, *J Lipid Res,* 45:1859-67, 2004

120. Maldonado A, He L, Game BA, Nareika A, Sanders JJ, London SD,
     **Lopes-Virella, MF** and Huang, Y.: Pre-exposure to high glucose
     augments LPS-stimulated matrix metalloproteinase 1 expression by
     human U937 histiocytes*. J Periodontal Research*, 39:415-423, 2004

121. Costacou T, Zgibor JC, Evans RW, Otvos J, **Lopes-Virella MF** and
     Orchard T: The role of adiponectin in coronary artery disease among
     individuals with type 1 diabetes. The Pittsburgh Epidemiology of
     Diabetes Complications (EDC) Study*, Diabetologia,* 48:41-8, 2005,
     electronic public Dec 23, 2004

122. Kraml,P, Klein RL, Huang Y, Nareika A and **Lopes-Virella MF**:
     Iron Loading enhances LDL uptake via MSR-I scavenger receptor in
     THP-1 macrophages, *Metabolism* 54:453-9, 2005

123. Virella G, Derrick MB, Pate, V, Chassereau C, Thorpe S and
     **Lopes-Virella MF**: Development of capture assays for different
     modifications of human low density lipoprotein, *Clinical and*
     *Diagnostic Laboratory Immunology*, 12:68-75, 2005

124. **Lopes-Virella MF**, Thorpe S, Derrick MB, Chassereau C, and
     Virella G: The immunogenicity of modified lipoproteins. *Annals of
     New York Academy of Sciences,* 1043: 367-378, 2005

125. Costacou T, Zgibor JC, Evans RW, **Lopes-Virella, MF,** Orchard T:
     Markers of endothelial dysfunction in the prediction of coronary
     heart disease in type 1 diabetes. The Pittsbutgh Epidemiology of
     Diabetes Complications study *Journal of Diabetes and its
     Complications*, 19:183-193,2005

126. Nareika A, He L, Game BA, Sanders JJ, London SD, **Lopes-Virella
     MF** and Huang Y. Sodium Lactate and Lipopolysaccharide exert
     synergistic effect on MMP and Cytokine Expression in U937
     Histiocytes through NfkB and MAPK Pathways. *American Journal of
     Physiology Endocrinol Met* 289: E534-E542, 2005

127. Yishak AA, Costacou T, Virella G, Zgibor J, Fried L, Walsh M, Evans
     RW, **Lopes-Virella MF**, Kagan VE, Otvos J and Orchard TJ: Novel
     predictors of overt nephropathy in subjects with type 1 diabetes. A
     nested case control study from the Pittsburgh Epidemiology of
     Diabetes Complications (EDC) cohort. *Nephr Dial Transpl*, 21:
     93-100, 2006

128. Lyons TJ, Jenkins AJ,Zheng D,Klein RL,Otvos JD,Yu Y, Lackland DT,
     McGee D,McHenry MB, **Lopes-Virella MF**, Garvey WT and the
     DCCT/EDIC Research Group. Nuclear Magnetic Resonance-determined
     Lipoprotein Subclass Profile in the DCCT/EDIC cohort: Association
     with Carotid Intima Media Thickness. *Diabetic Medicine*,
     23:955-66, 2006

129. Hammad SM, Taha TA, Nareika A, Johson KR, **Lopes-Virella MF** and
     Obeid, L: Oxidized LDL-Immune complexes induce release of
     sphingosine kinase in human macrophages. *Prostaglandins and Other
     Lipid mediators,* 79: 126-40, 2006

130. **Lopes-Virella, Maria F,** McHenry MB, Lipsitz s, Yim E, Wilson
     PF, Lackland DT, Lyons T, Jenkins AJ, Virella G and the DCCT/EDIC
     Research Group. Immune Complexes containing modified Lipoproteins
     are related to the progression of internal carotid intima-media
     thickness in patients with type 1 diabetes. *Atherosclerosis*, 190:
     359-369, 2007

131. Saad AF, Virella G, Chassereau C, Boackle RJ, **Lopes-Virella MF**:
     Autoimmune oxLDL Immune Complexes activate the classical pathway of
     complement and induce cytokine production by MonoMac cells and
     human macrophages, *J Lipid Res*, 47:1975-83, 2006

132. Game,BA, He L, Jarido V, Nareika A, Jaffa AA, **Lopes-Virella MF**
     and Huang,Y: Pioglitazone inhibits connective growth factor
     expression in advanced atherosclerotic plaques in low density
     lipoprotein receptor deficient mice. *Atherosclerosis*
     192:85-91,2007 (Epub on August 8,2006) 192: 85-91,2007

133. Nareika A, Maldonado A, He L, Game BA, Slate EH, Sanders JJ, London
     SD, **Lopes-Virella MF** and Huang Y: High glucose-boosted
     inflammatory responses to lipopolysaccharide are suppressed by
     statins. *J Periodontal Res* 42: 31-8, 2007

134. Carter, RE, Lackland DT, Cleary PA, Yim E, Lopes-Virella M, Gilbert
     GE, Orchard TJ and the DCCT/EDIC Research Team. Intensive Treatment
     of Diabetes is associated with a reduced rate of peripheral
     arterial calcification in Diabetes Control and Complications trial
     /Epidemiology of Diabetes Interventions and Complications
     (DCCT/EDIC). *Diabetes Care*, 30:2646-2648, 2007

135. Alena Nareika, Yeong-Bin Im, Bryan A. Game, Elizabeth H. Slate,
     John J. Sanders, Steven D. London, Maria F. Lopes-Virella, Yan
     Huang. High Glucose Enhances Lipopolysaccharide-Stimulated CD14
     Expression in U937 Mononuclear Cells by Increasing NFkB and AP-1
     Activities. *Journal of Endocrinology*, 196:45-55, 2008

136. Brock JW, Jenkins AJ, Lyons TJ, Klein RL, Yim E, Lopes-Virella M,
     Carter RE, Thorpe SR, Baynes JW, and the DCCT/EDIC Research Group:
     Increased methionine sulfoxide content of Apo A1 in type 1
     diabetes. *J Lipid Res* 49:847-55, 2008

137. Jaffa A, UsingerW, McHenry B, Lipsitz,S, Yan T, Wang B, Lackland D,
     Lopes-Virella MF, Luttrell L and Wilson P. Connective Tissue Growth
     factor and susceptibility to vascular disease risk in type 1
     diabetes. *The Journal of Clinical Endocrinology & Metabolism,*
     93:1893-900, 2008

138. Virella G, Carter RE, Saad A, Crosswell EG, Game BA and
     Lopes-Virella, MF: Distribution of IgM and IgG antibodies to
     oxidized LDL in immune complexes isolated from patients with type 1
     diabetes and its relationship with nephropathy. *Clinical
     Immunology,* 127:394-400, 2008

139. Virella, G. and Lopes-Virella, M.F. Atherogenesis and the Humoral
     Immune Response to Modified Lipoproteins. *Atherosclerosis*, in
     press, 2008.

140. Hammad, S.M., Twal, W.O., Barth, J.L., Smith, K.J., Saad, A.F.,
     Virella, G., Argraves, W.S., Lopes-Virella, M.F. Oxidized LDL
     immune complexes and oxidized LDL differentially affect the
     expression of genes involved with inflammation and survival in
     human U937 monocytic cells. *Atherosclerosis*, in press, 2008.

141. Lopes-Virella, MF, Carter R, Klein R, Jaffa M, Jenkins A, Lyons T,
     Garvey WT , Virella G and the DCCT/EDIC Group of Investigators:
     Risk factors related to Inflammation and Endothelial Dysfunction in
     the DCCT/EDIC cohort and their relationship with Nephropathy and
     macrovascular Complications. Diabetes Care. 31:2006-12, 2008.

142. Nareika A, Sundararaj KP, Im YB, Game BA, Lopes-Virella MF, Huang
     Y: High glucose and Interferon Gamma synergistically stimulate
     MMP-1 expression in U937 macrophages by increasing Transcription
     Factor STAT1 activity. Atherosclerosis , in print, 2008

143. Cole CM, Sundararaj KP, Leite RS, Nareika A, Slate EH, Sanders JJ,
     Lopes-Virella MF, Huang Y. A trend of increase in periodontal IL-6
     expression across patients with neither diabetes nor periodontal
     disease, patients with periodontal diseasealone, and patients with
     both diseases.  Journal of Periodontal Research, 43: 717-722, 2008.

144. Sundararaj KP, Li Y, Samuvel DJ, Nareika A, Slate EH, Sanders JJ,
     Lopes-Virella MF, Huang Y. Simvastatin Suppresses LPS-Induced MMP-1
     Expression in U937 Mononuclear Cells by Inhibiting Protein
     Isoprenylation-mediated ERK Activation, *Journal of Leukocyte
     Biology* 84: 1120-9, 2008.

145. Samuvel DJ, Sundararaj KP, Nareika A, Lopes-Virella MF, Huang Y.
     Lactate\
     Boosts TLR4 Signaling and NFkB Pathway-Mediated Gene Transcription
     in\
     Macrophages via Monocarboxylate Transporters and MD-2
     Upregulation*.  Journal\
     of Immunology*, in press, 2009

### Book Chapters

1\. **Lopes MF**. "Chronic Broncho-pulmonary Disease and
Mucoviscidosis - Determination of Sweat Chloride Concentrations."
Graduate thesis presented to the Medical School, Lisbon, 1967 (Port.).

2\. Colwell JA and **Lopes-Virella MF**. "Lipids and Lipoproteins in
Diabetes Mellitus." *Handbook of Diabetes Mellitus,Vol. IV*, ed.
Brownlee M, STPM Press, New York, 1981, pp 117-131.

3\. Virella G, **Lopes-Virella MF** and Estes G. "Nephelometric Assays
in Clinical Immunology." *Microbiology,* ed. by American Society of
Microbiology, 1981, pp. 326-331.

4\. **Lopes-Virella MF** and Virella G. "Immunochemical Determination of
Human Apolipoproteins by Laser Nephelometry." *Proceedings of the
Workshop on Apolipoprotein Quantification,* ed*.* Lippel K, NIH
Publication No. 83-1266, 1983, pp 289-304.

5\. Virella G and **Lopes-Virella MF**. "Diagnostic Value of
Quantitative Studies of Urinary Proteins." In: *Methods in Nephrology: A
Handbook for the Nephrological Team,* ed. Lubec G, J. Libbey, London,
1983, pp 150-160.

6\. **Lopes-Virella MF**. "Metabolism of Low Density and High Density
Lipoproteins by Cultured Cells." *Proceedings of the International
Symposium on Atherosclerosis in Diabetes Mellitus*, Osaka, Japan, 1986,
pp 155-163.

7\. **Lopes-Virella MF**. "Métabolisme Dès Lipoproteines Au Cours Du
Diabète Sucré." *Journées De Diabétologie Hôtel-Dieu,* M. Rathery,
Medecine-Sciences Flammarion, Paris, pp 55-66, 1987 (French).

8\. Colwell JA, **Lopes-Virella MF**, Winocour PD and Halushka PV. "New
Concepts about the Pathogenesis of Atherosclerosis in Diabetes
Mellitus." *Diabetic Foot*, 4th edition, ed. Levin M and O\'Neal LW,
C.V. Mosby Co., Washington, DC, 1987, pp 51-70.

9\. Colwell JA, Winocour P and **Lopes-Virella MF**. "Platelet Function
and Platelet Plasma Interactions in Arteriosclerosis and Diabetes
Mellitus." *Diabetes Mellitus, Theory and Practice,* ed. Ellenberg M and
Rifkin H, Elsevier Science Publishing Co., 1989, pp 249-256.

10\. **Lopes-Virella MF** and Virella G. "Virus and Arteriosclerosis, Le
Risque Vasculaïre." *Proceedings of the 4 èmes Recontrés Internationales
de Recherches et de Technologies*

*Méd0icales et Pharmaceutiques* (EUROMEDECINE 88), Montpellier, France,
1988, pp 400-402.

11\. **Lopes-Virella MF** and Virella G. "Immune Mechanisms in the
Pathogenesis of Arteriosclerosis." *Hypercholesterolemia,
Hypocholesterolemia, Hypertriglyceridemia.* Proceedings of the 5th
International Colloquium of the Fondation de Recherche sur
l\'Atherosclerosis, ed by C. L. Malmendier et al., Plenum Publishing Co
, New York, 1990, pp 383-392.

12\. **Lopes-Virella MF** and Virella G. "The Role of Immune Mechanisms
in the Pathogenesis of Atherosclerosis in Diabetes Mellitus."
*Proceedings of the XIV International Diabetes Federation Congress*,
Elsevier Publications, 1992.

13\. **Lopes-Virella MF** and Virella G. "Immune Mechanisms of
Atherosclerosis in Diabetes Mellitus." *Proceedings of the 9th
International Symposium on Atherosclerosis*, ed. Stein Y and Eisenberg
S, R&L Creative Communications, LTD., 1992.

14\. Colwell JA, Lyons TJ, Klein RL and **Lopes-Virella MF**. "New
Concepts about the Pathogenesis of Atherosclerosis and Thrombosis in
Diabetes Mellitus." *Diabetic Foot*, ed. Levin ME and O\'Neal LW, C.V.
Mosby Co., 1993, pp 79-114.

15\. Lyons TJ and **Lopes-Virella MF**. "Diabetes and Atherosclerosis:
Glycosylation Related Mechanisms." *Diabetes and Atherosclerosis*, ed.
Draznin B and Eckel R, Elsevier Science Publishing Co., 1993, pp
169-189.

16\. **Lopes-Virella MF**. "Interrelated Metabolism Imbalances Linked to
Hyperglycemia-induced Vascular Dysfunction*." Pathogenesis and Treatment
of NIDDM and Its Related Problems*, ed. Sakamoto N, Alberti KGMM and
Hotta N, Elsevier Science B.V., 1994, pp 29-36.

17. **Lopes-Virella MF** and Virella G. "Immune-mediated Mechanisms of
    Atherogenesis in Diabetes." *Diabetes*, ed. Baba S and Kaneko T,
    Elsevier Science B.V., 1995, pp 399-405

18. **Lopes-Virella MF**. "Biochemical Aspects of Macrovascular
    Disease." *International Textbook of Diabetes Mellitus*, 2nd
    edition, ed, Alberti KGMM, DeFronzo RA, Keen H and Zimmet P, John
    Wiley, 1:1631-1642, 1997

19. Colwell JA, Lyons TJ, Klein RL, **Lopes-Virella MF** and Jokl, RJ.
    "Atherosclerosis and Thrombosis in Diabetes Mellitus: New Aspects of
    Pathogenesis." *Diabetic Foot*, ed. Levin ME and O\'Neal LW, C.V.
    Mosby Co., 4:65-106, 2000

20. **Lopes-Virella MF**. "Diabetes and Atherosclerosis." in *Diabetes
    and Cardiovascular Disease*, ed by Johnstone M and Veves A., The
    Humana Press Inc, Totowa, NJ, pp 169-194, 2001

21. **Lopes-Virella MF**, Jenkins C and Mironova M*. "Nutrition in
    Diabetes Mellitus" in Handbook of Nutrition and Food*, ed by Feldman
    E and St.Jeor, CRC Press LLC, Roca-Baton, Florida, 53:1077-1111,
    2001

22. **Lopes-Virella MF** and G. Virella. Diabetes and Atherosclerosis,
    in *Contemporary Cardiology: Diabetes and Cardiovascular Disease,*
    2^nd^ Edition, eds MT Johnstone and A. Veves, pps 225-258, Humana
    Press Inc Totowa, NJ, 2006

23. John A Colwell, Timothy J Lyons, Richard L Klein, **Maria F
    Lopes-Virella**, Rudolf J Jokl. \"Atherosclerosis and Thrombosis in
    Diabetes Mellitus: New Aspects of Pathogenesis\" (pp. 89 - 113). in
    Levin and O\'Neal\'s The Diabetic Foot, 7th edition. John H Bowker
    and Michael A Pfeifer (eds).  Mosby, Inc. Philadelphia, PA. 2008

24. **Lopes**-**Virella MF** and Jenkins C*. "Nutrition in Diabetes
    Mellitus" in Handbook of Nutrition and Food*, ed by C.Berdanier, J.
    Dwyer and E.Feldman, CRC Press LLC, Roca-Baton, Florida, pps785-813,
    2008

**Abstracts (Presented at Meetings and/or Published)**

1\. **Lopes-Virella MF**, Stone P and Colwell JA. "Serum High Density
Lipoprotein (HDL) in Diabetic Patients." *Clin Res* 24:581A, 1976.

2\. **Lopes-Virella MF**, Virella G, Owens J, DeBeukelaer M, Garfinkel H
and Colwell JA. "Urinary Lipids and Lipoproteins in Patients with Kidney
Diseases." *Clin Res* 25:61A, 1977.

3\. **Lopes-Virella** **MF**, Virella G, DeBeukelaer M, Owens J and
Colwell JA. "Serum and Urinary Lipoproteins in Lipoid Nephrosis." *Clin
Res* 25:441A, 1977.

4\. **Lopes-Virella MF**, Stone P and Colwell JA. "Serum High Density
Lipoprotein in Diabetes Mellitus." Presented to the American College of
Physicians (58th Annual Session) Dallas, Texas, April 12-21, 1977.

5\. **Lopes-Virella MF**, Gonzalez J, Rosebrock G, Lichtenstein L, Sagel
J and Colwell JA. "High Density Lipoprotein Cholesterol (HDL-Chol) and
Apolipoprotein A Levels in Diabetics with and without Macrovascular
Disease." *Diabetes* 26 (Suppl 1):31, 1977. Presented to the American
Diabetes Association (37th Annual Meeting), St. Louis, Missouri, June
5-7, 1977.

6\. **Lopes-Virella MF**, Virella G, Gonzalez J, Rosebrock G and Colwell
JA. "Screening of Diabetic Nephropathy by Analysis of Urinary Proteins
using SDS-PAGE." *Diabetes* 26 (S1):272, 1977.

7\. **Lopes-Virella MF**, Rosebrock G, Virella G, Sagel J, Gonzalez J
and Colwell JA. "Analytical Study of Urinary Proteins in Diabetes."
*Diabetes* 27 (S2):490, 1978.

8\. **Lopes-Virella MF**, Virella G, Levine J, Ogawa M and Gonzalez J.
"Idiopathic Bence-Jones Proteinuria." *Clin Res* 26:351A, 1978.

9\. Sagel J, **Lopes-Virella MF**, Colwell JA and Levine JH. "Altered
High Density Lipoprotein Cholesterol (HDL-Chol) in
Hypothalamic-pituitary Disorders." *Clin Res* 26:758A, 1978.

10\. **Lopes-Virella MF**, Virella G, DeBeukelaer M, Owens J and Colwell
JA. "Absence of Apolipoprotein A in the Urines of Patients with Minimal
Change Glomerular Disease." *Clin Res* 26:805A, 1978.

11\. O\'Dell R, Adams K, **Lopes-Virella MF** and Virella G. "Post
Hemolytic Acute Renal Failure in Chronic CHD." International Colloquium
devoted to Cryoproteins, Grenoble, France, September 21-23, 1978.

12\. Mayfield RK, Levine JH, **Lopes-Virella MF**, Gordon L, Sagel J and
Buse MG. "Severe Hyperlipidemia Prevents Adrenal Imaging with
131-I-6-b-iodomethyl-19-norcholesterol (131-I-Chol)." *Clin Res*
27:257A, 1979.

13\. **Lopes-Virella MF** and Wohltmann H. "Plasma High Density
Lipoprotein Cholesterol (HDL-Chol) Increases with Control in
Insulin-dependent Young Male Diabetics." *Diabetes* 28(S 1): 16, 1979.
Presented to the American Diabetes Association, 39th Meeting, Los
Angeles, California, June 1979.

14\. Colwell JA, Halushka P, **Lopes-Virella MF**, Nair RMG, Sarji K and
Sagel J. "Vascular Risk Factors in Diabetes Mellitus." 10th Congress of
the International Diabetes Federation, Vienna, Austria, September 9-14,
1979.

15\. Gordon L, Mayfield RK, Levine JH, **Lopes-Virella MF**, Sagel J and
Buse MG. "Erroneous Negative Adrenal Imaging with
131-1-6-b-iodomethy1-19-norcholesterol (131-I-Chol)." Presented to the
Society of Nuclear Medicine 26th Annual Meeting, 1979.

16\. Virella G, Wohltmann H, Sagel J, **Lopes-Virella MF**, Kilpatrick M
and Colwell JA. "Detection of Soluble Immunocomplexes in Patients with
Diabetes Mellitus." *Diabetes* 29:323, 1980.

17\. **Lopes-Virella MF**, Sherer G, Wohltmann H, Mayfield R, Sagel J,
Leroy C and Colwell JA. *"In Vitro* behavior of LDL Isolated from
Insulin-dependent Diabetics. Relationship with Metabolic Control." *Clin
Res* 28: 891A, 1980. Presented to the Southern Society for Clinical
Investigation, New Orleans, Louisiana, January 1981.

18\. **Lopes-Virella MF**, Sherer G, Lees AM, Wohltmann H, Mayfield R,
Sagel J, Leroy C and Colwell JA. "Uptake and Degradation by Human
Fibroblasts of LDL Isolated from Diabetic Patients. Changes with
Metabolic Control." *Clin Res* 29: 425A, 1981. Presented to the National
Meeting of the American Federation for Clinical Research, San Francisco,
California, April 25-27, 1981.

19\. **Lopes-Virella MF**, Wohltmann H, Colwell JA and Mayfield R.
"Effect of Metabolic Control on Lipid, Lipoprotein and Apolipoprotein
Levels in Insulin Dependent Diabetes (IDDM)." *Diabetes* 31: 55, 1982.
Presented to the 42nd Annual Meeting of the American Diabetes
Association, San Francisco, California, June 1982.

20\. **Lopes-Virella MF**, Sherer G, Wohltmann H and Colwell JA.
"LDL-uptake and Degradation by Human Fibroblasts Incubated with Normal
or Diabetic Lipoprotein Deficient Sera (LPDS)." *Diabetes* 32: 58, 1983.
Presented to the 43rd Annual Meeting of the American Diabetes
Association, San Antonio, Texas, June 1983.

21\. **Lopes-Virella MF**, Mordes D, Harstine L and Colwell J. "Plasma
Hepatic and Lipoprotein Lipase Activities after Prolonged Infusion of
Heparin in Type II Diabetic Females." *Clin Res* 31: 851A, 1983.
Presented at the Southern Society for Clinical Investigation, New
Orleans, Louisiana, January 1984.

22\. Mayfield R, Halushka P, Wohltmann H, Colwell J and **Lopes-Virella
MF**. "Effects of Glycemic Control on Platelet Function in
Insulin-dependent Diabetes Mellitus." *Diabetes* 33:208,1984. Poster
Presentation at the 44th Annual Meeting of the American Diabetes
Association, Las Vegas, Nevada, June 10-13, 1984.

23\. **Lopes-Virella MF**, Mordes D, Harstine L and Colwell JA.
"Comparison of Plasma Hepatic and Lipoprotein Lipase Activities during
Prolonged Heparin Infusion in Control and Type II Diabetic Females."
*Diabetes*, 33:625, 1984.

24\. **Lopes-Virella MF**, Klein RL and Stevenson HC. "Enhancement of
Cholesteryl Ester Synthesis in Human Macrophages Activated by Bacterial
Lipopolysaccharides and Muramyl Dipeptide." *Clinical Research* 33:436A,
1985.

25\. **Lopes-Virella MF**, Klein RL and Stevenson HC. "Infectious
Processes may Accelerate Atherosclerosis in Diabetes Mellitus."
*Diabetes* 34:257, 1985. Poster presentation at the 45th Annual Meeting,
American Diabetes Association, Baltimore, Maryland, June, 1985.

26\. **Lopes-Virella MF**, Sherer G, Wohltmann H, Sens D and Colwell JA.
"Diabetic Lipoprotein Deficient Serum (LPDS) Inhibits Low Density
Lipoprotein (LDL) Receptor Activity." *Arteriosclerosis* 5:511a, 1985.

27\. **Lopes-Virella MF**, Klein RL, Lyons T, Stevenson HC and Witztum
JL. "*In Vitro* Glucosylated LDL (Glu-LDL) Enhances Cholesteryl Ester
(CE) Synthesis in Human Monocyte-derived Macrophages." *Circulation*
77:817, 1985 and *Arteriosclerosis* 5:507a, 1985. Presented to the 58th
Annual Meeting, American Heart Association, Washington, DC, November
11-14, 1985.

28\. Lyons TJ, Klein RL, Baynes JW and **Lopes-Virella MF**.
"Stimulation of Cholesteryl Ester (CE) Synthesis in Human
Monocyte-derived Macrophages by LDL Isolated from Diabetic Patients."
*Clin Res* 34:208A, 1985. Presented to the Southern Society for Clinical
Investigation, New Orleans, Louisiana, February 1986.

29\. Lyons TJ, Klein RL, Patrick JS, **Lopes-Virella MF** and Baynes JW.
"Glycation of Plasma Lipoproteins in Diabetes: Correlation with Other
Indices of Glycemic Control and Effects on Cholesterol Metabolism in
Macrophages." Presented to the American Society of Biologic Chemists,
Washington, DC, May 1986.

30\. Lyons TJ, Klein RL, Baynes J and **Lopes-Virella MF**. "VLDL and
LDL from Diabetic Patients Stimulate Increased Cholesteryl Ester (CE)
Synthesis in Human Monocyte-derived Macrophages." *Diabetes* 35:266,
1986.

31\. **Lopes-Virella MF**, Klein RL, Lyons TJ, Stevenson HC and Witztum
JL. "Metabolism of *in vitro* Glucosylated LDL (91c-LDL) by Human
Monocyte-derived Macrophages." *Diabetes* 35:356, 1986. Presented to the
46th Annual Meeting of the American Diabetes Association, Anaheim,
California, June 21-24, 1986.

32\. **Lopes-Virella MF**, Klein RL and Stevenson HC. "Possible Role of
Infectious Processes in the Acceleration of Atherosclerosis." Presented
to the Annual Meeting of the American College of Physicians, South
Carolina Chapter and South Carolina Society of Internal Medicine,
October 10-12, Kiawah, South Carolina, 1986.

33\. **Lopes-Virella MF**, Wohltmann JH, Klein RL and Stevenson HC. "CE
Synthesis in Human Macrophages Exposed to VLDL Isolated from Type I
Diabetic Patients." *Diabetes* 36:101, 1987.

34\. Klein RL, Lyons TJ, Stevenson HC and **Lopes-Virella MF**.
"Interaction of VLDL Isolated from Type II Diabetic Subjects with Human
Macrophages." *Diabetes* 36:103, 1987.

35\. Griffith RL, Virella GT, Stevenson HC and **Lopes-Virella MF**.
"LDL-immune Complex Activation of Human Macrophages: A Possible Role in
Foam Cell Formation." *Arteriosclerosis* 7:5479, 1987.

36\. Griffith RL, Virella GT, Stevenson HC and **Lopes-Virella MF**.
"Alteration of Native LDL Metabolism in Immune Complex Stimulated Human
Macrophages." *Arteriosclerosis* 7:546a, 1987.

37\. Griffith RL, Virella GT, Stevenson HC and **Lopes-Virella MF**.
"LDL Metabolism by Macrophages Activated with Low Density Lipoprotein
Immune Complexes: A Possible Mechanism of Foam Cell Formation." *Clin
Res*. 36: 31A, 1988. Presented to the Southern Society for Clinical
Investigation, New Orleans, Louisiana, February 1988.

38\. Klein RL and **Lopes-Virella MF**. "Interaction of VLDL
Subfractions Isolated from Type 1 Diabetic Subjects with Human
Endothelial Cells." *Diabetes* 37:274, 1988.

39\. Dunn FL, Cleary PA, Schrott HG, Oexmann MJ, Castle G, Steffes MW,
**Lopes-Virella** **MF** and Nathan DM for the DCCT Research Group.
"Lipid Levels in Patients with Type I Diabetes: Baseline Studies in the
DCCT." *Diabetes* 37:838, 1988.

40\. Griffith RL, Virella GT, Stevenson MF and **Lopes-Virella MF**.
"Low Density Lipoprotein (LDL) Metabolism by Human Macrophages Activated
with Low Density Lipoprotein Immune Complexes: A Possible Mechanism of
Foam Cell Formation." Presented at the 8th International Symposium on
Atherosclerosis, Rome, Italy, October 9-13, 1988.

41\. Griffith RL, Virella GT, Stevenson HC and **Lopes-Virella MF**.
"Abnormal Low Density Lipoprotein (LDL) Metabolism in Immune Complex
(IC)-stimulated Human Macrophages." Presented at the 8th International
Symposium on Atherosclerosis, Rome, Italy, October 9-13, 1988.

42\. Ascensão JL, Klein RL and **Lopes-Virella MF**. "Interleukin-1
Stimulates the Degradation of Low Density Lipoprotein by Human
Endothelial Cells." *Clinical Research* 37:404 A, 1989.

43\. Gisinger C, Virella G and **Lopes-Virella MF**. "Increased LDL
Binding by Human Monocyte Derived Macrophages after Stimulation with
Erythrocyte-bound LDL Immune Complex." Presented to the International
Atherosclerosis Congress, Vienna, Austria, April 20-22, 1989.

44\. Klein RL, Gisinger C and **Lopes-Virella MF**. "Interaction of
Human Monocyte-derived Macrophages with Glycosylated and
Non-glycosylated Subfractions of Low Density Lipoprotein (LDL) Isolated
from Diabetic Patients." *Diabetes* 38: 279, 1989. Presented to the
International Atherosclerosis Congress, Vienna, Austria, April 20-22,
1989 and to the 49th Annual Meeting of the American Diabetes
Association, Detroit, Michigan, June 1989.

45\. Stevens J, **Lopes-Virella MF**, Sutherland SE, Keil JE and Gazes
PC. "Serum Lipids in the Elderly Charleston Heart Study Cohort and
Correlations with BMI." Presented to the 2nd International Conference on
Preventive Cardiology and the 29th Annual Meeting of the AHA Council on
Epidemiology, Washington, DC, June 18-22, 1989.

46\. Griffith RL, Virella G and **Lopes-Virella MF**. "LDL-containing
Immune Complexes and Foam Cell Formation." Presented to the 30th Annual
Meeting of the American College of Nutrition, Norfolk, Virginia,
September 1989.

47\. Griffith RL, Virella G and **Lopes-Virella MF**. "Lipoproteins,
Immune Complexes, and Foam Cell Formation." *Arteriosclerosis*, 9:735a,
1989.

48\. Griffith RL, Leman R, Virella G and **Lopes-Virella MF**. "LDL and
Modified LDL Autoantibodies in Normal Subjects and Patients with
Coronary Heart Disease." *Arteriosclerosis*, 9:735a, 1989.

49\. Gisinger C, Virella GT and **Lopes-Virella MF**. "The Uptake of
Soluble Lipoprotein Immune Complexes by Macrophages Induces Foam Cell
Formation and Enhances LDL Receptor Expression." *Circulation* 80:653,
1989 and *Arteriosclerosis*, 9:735a, 1989. Presented to the 62nd
National Meeting of the American Heart Association, New Orleans,
Louisiana, November 13-16, 1989.

50\. Gisinger C, Virella G and **Lopes-Virella MF**. "Metabolism of
Soluble LDL-immune Complexes by Macrophages: Evidence of Intracellular
Antigen-antibody Dissociation and Disturbed LDL Degradation." Presented
to the 5th International Colloquium, Fondation de Recherche sur
l\'Atherosclerose, Brussels, Belgium, March 14-16, 1990.

51\. Gisinger C, Virella G and **Lopes-Virella MF**. "Erythrocyte-bound
Soluble Immune Complexes Induce Cholesteryl Ester Accumulation in Human
Monocyte Derived Macrophages." *Diabetes* 39:175, 1990. Presented to the
50th Annual Meeting of the American Diabetes Association, Atlanta,
Georgia, June 16-19, 1990.

52\. Klein RL, **Lopes-Virella MF** and Colwell JA. "Enhancement of
Platelet Aggregation by the Glycosylated Sub-fraction of LDL Isolated
from Patients with IDDM." *Diabetes* 39: 173, 1990. Presented to the
50th Annual Meeting of the American Diabetes Association, Atlanta,
Georgia, June 16-19, 1990.

53\. Virella IL, Fourspring K, Leman RB, **Lopes-Virella MF** and
Virella G. "Development of an Enzymoimmunoassay for Antibodies to Human
Oxidized LDL." Presented to the American Society for Microbiology,
Myrtle Beach, South Carolina, November 16-18, 1990.

54\. Virella G, Fourspring K, Hyman B and **Lopes-Virella MF**.
"Depression of Humoral Immunity by Fish Oil Extracts." *FASEB Journal*
5:A1448, 1991. Presented at the FASEB Meeting, Atlanta, Georgia, April
21-25, 1991.

55\. Shunk KA and **Lopes-Virella MF**. "Mechanism of Cholesteryl Ester
(CE) Accumulation in Human Monocyte/Macrophages (HMM) Stimulated with
LDL: Anti-LDL Complexes (LDL-IC)." *Clinical Research* 39:800A, 1991.
Presented to the Southern Society for Clinical Investigation, New
Orleans, Louisiana, January 29-31, 1992.

56\. Jokl R, Klein RL, Colwell JA and **Lopes-Virella MF**. "Low Density
Lipoproteins Isolated from Diabetic Patients Alter the Release of Tissue
Plasminogen Activator (tPA) by Cultured Human Endothelial Cells."
*Diabetes* 41:173, 1992. Presented to the 52nd meeting of the American
Diabetes Association, San Antonio, Texas, June 20-23, 1992.

57\. Jokl R, Li W, Colwell JA, Klein RL, **Lopes-Virella MF** and Lyons
TJ. "Glycoxidized LDL Modifies PAI-1 Release by Retinal Endothelial
Cells." Presented to the 28th meeting of the European Association for
the Study of Diabetes, Prague, Czechoslovakia, September 8-11, 1992.

58\. Munoz J, Virella G, Galbraith G and **Lopes-Virella MF**.
"LDL-immune Complexes Activate Respiratory Burst and Cytokine Release in
Human Monocyte-derived Macrophages." *Circulation* 86: 1334, 1992.
Presented at the 65th National Meeting of the American Heart
Association, New Orleans, Louisiana, November 16-19, 1992.

59\. Virella G and **Lopes-Virella MF**. "Autoimmunity and
Atherosclerosis." *J.Immunol* 150:238A,1993. Presented to the American
Association of Immunologists and the Clinical Immunology Society,
Denver, Colorado, May 22-26, 1993.

60\. **Lopes-Virella MF**, Peng Y-G and Chassereau CH. "Cyclosporine and
Impaired Degradation by Human Monocyte-derived Macrophages of LDL
Isolated from Heart-transplanted Patients." *Circulation,* 87: 1993.
Presented at the 66th National Meeting of the American Heart
Association, Atlanta, Georgia, November 8-11, 1993.

61\. **Lopes-Virella MF**, Carter TD, Cutter GR, Hogan EL and Gaines KJ.
"Race and Gender-Differences of Lipid/Lipoproteins in Stroke Patients -
SECORDS Study." *Circulation,* 88:1994. Presented at the 67th National
Meeting of the American Heart Association, Dallas, Texas, November
14-17, 1994.

62\. **Lopes-Virella MF** and Virella G. "Immune-Mediated Mechanisms of
Atherogenesis in Diabetes." Presented at the 15th International Diabetes
Federation Meeting, Kobe, Japan, November 6-11, 1994.

63\. **Lopes-Virella MF**. "Cytokines, Modified Lipoproteins and
Arteriosclerosis in Diabetes Mellitus." Presented at the Symposium on
Diabetes and Macrovascular Complications, Osaka, Japan, November 12-13,
1994.

64\. Virella G and **Lopes-Virella MF**. "Autoimmunity and
Atherosclerosis." *Arquivos de Medicina* 8(S1):31, 1994.

65\. Virella G, Mironova M, Virella I and **Lopes-Virella MF**.
"Competitive vs Differential Assays for Antibodies to Modified LDL."
*FASEB Journal* 9: A1030,1995. Presented at the FASEB Meeting, Atlanta,
Georgia, 1995.

66\. Mironova M, Virella G and **Lopes-Virella MF**. "Isolation and
Characterization of Human Antibodies Against Oxidized LDL." *FASEB
Journal* 9: A1030,1995. Presented at the FASEB Meeting, Atlanta,
Georgia, 1995.

67\. Jokl R, Klein RL, Jenkins AJ, **Lopes-Virella MF** and Colwell JA.
"Oral Vitamin E Supplementation Does Not Affect Platelet Plasminogen
Activator Inhibitor-1 (PAI) Release in NIDDM Patients." *Diabetes*
44(S1):62A, 1995. Presented to the American Diabetes Association 55th
Annual Meeting and Scientific Sessions, Atlanta, Georgia, June 13-15,
1995.

68\. Jenkins A, Chassereau C, Klein RL and **Lopes-Virella MF**. "*In
Vitro* LDL Oxidizability is Not Increased in Patients with Well
Controlled IDDM." *Diabetes* 44(S1):43A, 1995. Presented to the American
Diabetes Association 55th Annual Meeting and Scientific Sessions,
Atlanta, Georgia, June 13-15, 1995.

69\. **Lopes-Virella MF**, Mironova M, Chassereau C, Fair EC, Virella I
and Virella G. "Transformation of Human Macrophages into Foam Cells
Induced by Immune Complexes Isolated from Diabetic and Control
Subjects." *Diabetes* 45(S2):995A, 1996.

70\. Ghosh M, Huang Y and **Lopes-Virella MF**. "Modified LDL-immune
Complexes Upregulates Macrophage Scavenger Receptors in THP-1 Cells."
Council on Arteriosclerosis for the *69th Scientific Sessions of the
AHA*, A1060, 1996.

71\. Huang Y, Ghosh M and **Lopes-Virella MF**. "Transcriptional and
Post-transcriptional Regulation of the LDL Receptor Gene in THP-1 Cells
Stimulated by LDL-IC." Council on Arteriosclerosis for the *69th
Scientific Sessions of the AHA*, A1075, 1996.

72\. Huang Y, Ghosh M and **Lopes-Virella MF**. "Massive Increase in
ACAT Activity Induced by Fc Receptor Mediated Uptake of LDL-IC." Council
on Arteriosclerosis for the *69th Scientific Sessions of the AHA*,
A1078, 1996.

73\. Virella G, Mironova M and **Lopes-Virella MF**. "The Atherogenic
Potential of Anti-LDL Antibodies." *J. Allergy Clin. Immunol.* 99:S22,
1997.

74\. Koskinen S, **Lopes-Virella MF** and Virella G. "Standardization of
an Enzymoimmunoassay for Measurement of Anti-oxLDL Antibodies."
*Diabetes*, 47(S1):A365, 1998.

75\. **Lopes-Virella MF** and Huang Y. "Oxidized LDL-Containing Immune
Complexes Stimulate Mitogen-Activated Protein (MAP) Kinase in
Macrophages." *Journal of Investigative Medicine*, 46:232A, March 1998.
Poster presentation at Biomedicine '98, Washington, DC, May 2, 1998.

76\. Takei A, Huang Y and **Lopes-Virella MF**. "Intercellular Adhesion
Molecule-1 (ICAM-1) Expression Induced by ox LDL on Human Umbilical Vein
Endothelial Cells (HUVEC) Depends on the Stage of LDL Oxidation."
*Diabetes*, 47(S1):A115, 1998. Poster presentation at the American
Diabetes Association 58th Annual Scientific Sessions, Chicago, Illinois,
June 13-16, 1998.

**77. Lopes-Virella MF**, Koskinen S, Virella G and Orchard T. "Oxidized
LDL antibodies and Immune Complexes Predict Coronary Artery Disease
(CAD) in Type 1 Diabetes." Diabetes, 47(S1):A53, 1998. Presented at the
American Diabetes Association 58th Annual Scientific Sessions, Chicago,
Illinois, June 13-16, 1998.

78\. Huang Y, Mironova M and **Lopes-Virella** **MF**. "Oxidized Low
Density Lipoprotein Stimulates Matrix Metalloproteinase 1 in Human
Vascular Endothelial Cells." Presented at the American Heart Association
71st Annual Meeting, Dallas, Texas, November 8-11, 1998.

79\. Takei A, Crawford A, Huang Y and **Lopes-Virella MF**. "Advanced
Glycation End-Products-LEL Stimulates Adhesion Molecule Expression by
Human Aortic Endothelial Cells." Presented at the American Diabetes
Association 59th Annual Scientific Meetings and Sessions, San Diego,
California, June 19-22, 1999.

80\. Huang Y, Fleming AJ, and **Lopes-Virella, MF**: LDL-containing
immune complexes induce macrophage matrix metalloproteinase-1 expression
via activation of a Fc gamma receptor I-linked mitogen activated protein
kinase pathway. Presented at the American Heart Association, 72nd Annual
Meeting, Atlanta, Georgia, November 7-10, 1999.

81\. Fu Y, Luo N, **Lopes-Virella, MF**: IL 8 expression induced by
glycated LDL in THP-1 macrophages. American Diabetes Association, 60th
Annual Scientific Meetings and Sessions, San Antonio, Texas, June, 2000.

82\. Atchley D**, Lopes-Virella, MF**, Zheng D, Virella G and DCCT/EDIC
Research Group: The Pathogenic Role of Immune Complexes formed by
Oxidized LDL and its Corresponding Antibodies in Diabetic Nephropathy.
American Diabetes Association, 61st Annual Meeting , Philadelphia,
Pennsylvania, *Diabetes*, 50(S2):A172,June, 2001

83\. Xu M, Game BA, **Lopes-Virella MF**, Huang Y. Insulin sensitizer
troglitazone stimulates matrix metalloproteinase-1 expression in human
vascular endothelial cells. Presented at the American Diabetes
Association, 61st Annual Meeting, Philadelphia, Pennsylvania,
*Diabetes*, 50(S2):A170, June, 2001.

84\. Game B.A., Maldonado, A. P., **Lopes-Virella, MF** and Huang, Y:
Crosslinking of Fcγ receptor I and II synergistically stimulates
extracellular signal-regulated kinase that induces AP-1 and Ets-mediated
matrix metalloproteinase-1 expression in U937 histiocytes. Presented at
the American Heart Association, 75nd Annual Meeting, Chicago, Illinois,
November 17-20, 2002. Circulation 106, suppl, 4, 2002

85. Vielma, SA, Krings G, **Lopes-Virella, MF**: Protein Kinase C and
    Nuclear Factor-Kappa B Signaling Pathways Mediate the Upregulation
    of Intracellular Adhesion Molecule-1 Induced by *Chlamydophila
    pneumoniae.* Accepted for presentation at the 4th Annual Conference
    on Arteiosclerosis, Thrombosis and vascular Biology, May 8-10, 2003,
    Washington DC

86. Yishak AA, Virella G, Zgibor JC, Walsh, Costacou T, Evans RW,
    **Lopes-Virella MF**, Kagan VE, Orchard T: Role of immune complexes,
    oxidized LDL antibody and total oxidative reserve in diabetic
    nephropathy. Presented at the International Diabetes Federation
    Meeting, Paris, August 24-29, 2003.

87. Costacou T, Zgibor JC, Walsh M, **Lopes-Virella MF**, Otvos J,
    Orchard T: Why is E-selectin such a good predictor of CAD in type 1
    diabetes? The Pittsburgh Epidemiology of Diabetes Complications
    Study. Presented at the National American Heart Association Meeting,
    Orlando, November 7-11, 2003

88. Andrea J. Semler, M. Brent McHenry, Daniel T. Lackland, Stuart R.
    Lipsitz, **Maria-Lopes Virella**, W. Timothy Garvey, Richard L.
    Klein, and the DCCT/EDIC Research Group : Associations of
    Adiponectin with Retinopathy in the DCCT/EDIC Cohort: Influence of
    Insulin Resistance. To be presented at the American Diabetes
    Association, 64st Annual Meeting, June 4-8, 2004, Orlando, Florida.

89. G.Virella, M. B. Derrick, C. Chassereau, S. R. Thorpe, and **M. F.
    Lopes-Virella**. The autoimmune response to modified human
    low-density lipoprotein. Clinical Immunology, Suppl.1: S211, 2005.

90. Silvana A. Vielma, J-R Ku, J. Bieawski, Obeid L, Virella, G, M Munoz
    and **M.F. Lopes-Virella:** Chamydophila pneumoniae alters the
    metabolism of sphiongolipids and triggers an extensive coalescence
    of lipid rafts in human monocytic cells. Presented at the 6^th^
    Annual conference on Arteriosclerosis, Thrombosis and Vascular
    Biology, April 28-30,2005, Washington , DC

91. Alena Nareika, Lin He, Bryan A. Game, J.J. Sanders, S.D. London ,
    **MF Lopes-Virella** and Y. Huang,: Sodium Lactate and LPS exert
    synergistic effect on MMP and cytokine expression in U937
    histiocytes through NfkB and MAPK pathways. *Diabetes* 54: suppl 1;
    1287-P, 2005.

92\. Bryan A. Game, Lin He, V. Jarido, A. Jaffa, **MF Lopes-Virella**
and Y. Huang,: Pioglitazone inhibits connective tissue growth factor
expression during the progression of aortic atherosclerotic Plaque in
LDL Receptor-deficient mice. Diabetes 54: suppl 1; 750-P, 2005.

93\. **Lopes-Virella MF**, Lipsitz S, Wilson P, Lackland D, Lyons T,
Jenkins A, Garvey WT, Virella G and the DCCT/EDIC Study Group. Modified
Lipoprotein Immune Complexes and Progression of Internal Carotid Intima
Medial Thickness in type 1 diabetes. Presented at the American Heart
Association scientific sessions, Nov 13-16, 2005, Dallas, TX.

94\. Jaffa A, Usinger WR, McHenry H, Lipsitz S, Lackland D, Luttrell L,
Wilson PW, **Lopes-Virella MF** and the DCCT/EDIC Study Group. El;evated
CTGF levels are an independent risk marker of diabetic vascular disease.
Presented at the American Society for Nephrology, Nov 8-13, 2005,
Philadelphia, PA.

95\. Lok KH, Klein RL, Lyons TJ, **Lopes-Virella, MF**, Jenkins AJ, Yim
E, Carter R,Garvey WT and the DCCT/EDIC Study Group: CETP gene variation
has pronounced independent effect on HDL levels and HDL particle size in
type 1 diabetes. Presented at the American Diabetes Association annual
meeting, Washington DC June 9-13, 2006. Diabetes, 55, suppl 1, 1066-P,
2006.

96\. Nareika A, Im Y-B, Game BA, Slate EH, Sanders JJ, London SD,
**Lopes-Virella, MF** and Huang Y. High glucose markedly enhances
lipopolysaccharide-induced CD14 expression in U937 histiocytes..
Presented at the American Diabetes Association annual meeting,
Washington DC June 9-13, 2006. Diabetes, 55, suppl 1, 722-P, 2006.

97\. ,Nareika A, Maldonado A, He L, Game BA, Slate EH, Sanders JJ,
London SD, **Lopes-Virella, MF** and Huang Y. Presented at the American
Diabetes Association annual meeting, Washington DC June 9-13, 2006.
Diabetes, 55, suppl 1, 679-P, 2006.

98\. Lopes-Virella MF, Moritz, T. Luo P, Duckworth W, Abraira, C,
Virella G and the VADT Study Group: Modified LDL-Immune complexes
predict progression of albuminuria in type 2 DM. Accepted for
presentation at the Endocrine Society 89^th^ Annual meeting, Toronto,
Canada, June 2-5, 2007

99\. Carter, RE, Cleary PA, Lackland DT, Yim E, Gilbert GE,
Lopes-Virella M, Nathan DM, Orchard TJ and the DCCT/EDIC Research Team.
Intensive Treatment of Diabetes is associated with a reduced rate of
peripheral arterial calcification in Diabetes Control and Complications
trial /Epidemiology of Diabetes Interventions and Complications
(DCCT/EDIC). Accepted for presentation at the 67^th^ annual meeting of
the American Diabetes association, Chicago, Illinois, June 22-26, 2007

100\. Christine M. Cole, Kamala P. Sundararaj, Renata S. Leite, Alena
Nareika, Elizabeth H. Slate, John J. Sanders, Maria F. Lopes-Virella,
Yan Huang. Periodontal IL-6 Expression in Diabetic and Nondiabetic
Patients. Presented at the American Association of Dental Research
Annual Meeting, Dallas, TX, April 2-5, 2008.

101\. Sundararaj KP, Li Y, Samuvel DJ, Nareika A, Lopes-Virella MF,
Huang Y.\
Simvastatin Suppresses LPS-Induced MMP-1 Expression in U937 Mononuclear\
Cells by Inhibiting Ras and Rac Protein Isoprenylation-mediated ERK\
Activation.  Presented at the American Heart Association
Atherosclerosis, Thrombosis and Vascular Biology annual meeting,
Atlanta, Georgia, April 16-18, 2008.

102\. Gabriel Virella, Rickey E. Carter, Antonio Saad, Edward G.
Crosswell, B. Andrew Game, the DCCT/EDIC Study Group and Maria F.
Lopes-Virella. Distribution of IgM and IgG antibodies to oxidized LDL in
immune complexes isolated from patients with type 1 diabetes and its
relationship with nephropathy. *Clinical Immunology*, 127
(suppl.):S77-78, 2008, Presented at the FOCI annual meeting, Boston, MA
5-8 June, 2008

103\. Sundararaj KP, Samuvel DJ, Li Y, Slate EH, Sanders JJ,
Lopes-Virella MF, Huang Y. High glucose enhances fibroblast-mononuclear
cell co-culture-boosted MMP-1 expression. Presented at the 68^th^
American Diabetes Association Scientific Sessions in San Francisco, CA,
June 6-10, 2008.

104\. Devaraj S, Lopes-Virella MF and Jialal I: Increased Circulating
Immune Complexes and Fc gamma receptor expression on monocytes of
patients with type 1 diabetes with microvascular complications.
Presented at the American Diabetes Association Scientific Sessions in
San Francisco, CA, June 6-10, 2008.